Composition for pet drinking water
By using amino acids that activate umami receptors and amino acids that cannot activate umami receptors in pet food, combining milk proteins and nucleotides, the problem of insufficient intake of cat water is solved, and chronic kidney disease and urinary tract is achieved Effective prevention and treatment of diseases improves the nutrition and taste of pet food.
Patent Information
- Application Number
- CN202380030044.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-24
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-08
AI Technical Summary
Cats are prone to urinary and renal health problems due to their biological properties and dietary habits, such as chronic kidney disease and urinary tract diseases, and the prior art is difficult to effectively increase their water intake to prevent these health challenges.
Provided a flavor composition, comprising amino acids capable of activating umami receptors and amino acids that cannot activate umami receptors, binds milk proteins and nucleotides or derivatives thereof, for the preparation of pet food to increase water consumption in cats. Intake, prevent and treat urinary tract and kidney diseases.
It significantly increases the water intake of cats, effectively prevents and treats chronic kidney disease and urinary tract diseases, improves kidney health, and enhances the palatability and nutritional value of pet food.
Smart Images

Figure CN118922084A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 323,309, filed on March 24, 2022, the contents of which are incorporated herein by reference in their entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing submitted electronically in XML format, which is incorporated herein by reference in its entirety. The XML copy was created on March 20, 2023, named 069269.0609_ST26.xml, and is 5147 bytes in size. Technical Field
[0005] The presently disclosed subject matter relates to compositions and / or compounds that increase water intake in cats. Increasing water intake is beneficial for maintaining and improving urinary tract and kidney function and health. Background Art
[0006] Cats (Felis catus) are obligate carnivores (Bradshaw et al., Comparative Biochemistry and Physiology Part A: Physiology 114, no. 3 (1996): 205-209) and are originally desert animals; therefore, they tend to meet most of their water needs by eating prey, which usually contains more than 75% water, and they naturally drink only small amounts of water (Burger et al., Nutrition of the dog and cat, pp 145-156. (1980). Ed. RS Anderson. Oxford. Pergamon Press. From a physiological standpoint, cats are able to produce more concentrated urine (urine specific gravity [SG] up to 1.095 g / mL) than humans (up to 1.040 g / mL) or dogs (up to 1.065 g / mL) (Markwell et al., Proceedings from the 9th International Symposium on Urolithiasis. 2000; Osborne and Nwaokorie. When urine specific gravity values goawry in veterinary practice. DVM360 Magazine, July 01, 2013), allowing them to respond to water restriction by reducing water losses in the urine. However, because this may lead to an increased risk of renal and urinary tract pathology, many dietary strategies for cats are aimed at increasing water intake to prevent or reduce urinary mineral saturation and crystallization, similar to the approach taken in humans (Borghi et al., The Journal of Urology 155.3 (1996): 839-843; Borghi et al., Nephron 81. Suppl. 1 (1999): 31-37).Therefore, there is a need to develop novel preventive and therapeutic strategies for urinary tract pathologies that would also help prevent secondary kidney health challenges such as chronic kidney disease (Bartlett et al., Veterinary Medicine International 2010 (2010): 957570). Summary of the invention
[0007] The present disclosure relates to compositions and / or compounds that increase water intake in cats.
[0008] In one aspect, the present disclosure provides a method for preventing and / or treating chronic kidney disease in an animal in need thereof. In another aspect, the present disclosure provides a method for preventing and / or treating urinary tract disease in an animal in need thereof. In certain embodiments, the method comprises administering a pet food comprising a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor.
[0009] In yet another aspect, the present disclosure provides a method for increasing the amount of water an animal drinks. In addition, in one aspect, the present disclosure provides a method for increasing hydration in an animal. In addition, in one aspect, the present disclosure provides a method for preventing and / or treating chronic kidney disease. In addition, in another aspect, the present disclosure provides a method for preventing and / or treating urinary tract diseases in an animal. In certain embodiments, the method comprises administering a pet food comprising milk protein and nucleotides or derivatives thereof.
[0010] In certain embodiments, the first amino acid is alanine, histidine, glycine, serine, tyrosine, or a mixture thereof. In certain embodiments, the second amino acid is proline, hydroxyproline, valine, threonine, lysine, or a mixture thereof. In certain embodiments, the first amino acid is alanine, histidine, glycine, serine, tyrosine, or a mixture thereof; and the second amino acid is proline, hydroxyproline, valine, threonine, lysine, or a mixture thereof. In certain embodiments, the first amino acid is histidine and any of the second amino acids listed. In certain embodiments, the first amino acid is histidine, and the second amino acid is proline, hydroxyproline, valine, threonine, lysine, or a mixture thereof. In certain embodiments, the first amino acid is alanine, histidine, glycine, serine, tyrosine, or a mixture thereof, and the second amino acid is proline. In certain embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In certain embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 1mM to about 1M. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 100 mM. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 20 mM to about 50 mM.
[0011] In certain embodiments, the pet food contains no phosphates or derivatives thereof and / or contains no furans or derivatives thereof. In certain embodiments, the pet food further contains yeast extract.
[0012] In certain embodiments, the milk protein is casein or a derivative thereof. In certain embodiments, the amount of the milk protein is about 1 wt % to about 10 wt %. In certain embodiments, the amount of the milk protein is about 3 wt %.
[0013] In certain embodiments, the nucleotide or its derivative is AMP, UMP, GMP, IMP, CMP or a mixture thereof. In certain embodiments, the nucleotide mixture comprises GMP and IMP. In certain embodiments, the nucleotide or its derivative is GMP. In certain embodiments, the nucleotide or its derivative is IMP.
[0014] In certain embodiments, the nucleotide or derivative thereof is obtained from a yeast extract. In certain embodiments, the yeast extract is a Kluyveromyces yeast extract, a Torulayeast extract, or a Saccharomyces cerevisae yeast extract.
[0015] In certain embodiments, the amount of nucleotides or derivatives thereof is about 1 mM to about 100 mM. In certain embodiments, the amount of nucleotides or derivatives thereof is about 5 mM.
[0016] In some embodiments, the pet food further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone (furaneol). In some embodiments, the amount of furan or a derivative thereof is about 1 ppm to about 100 ppm. In some embodiments, the amount of furan or a derivative thereof is about 4 ppm.
[0017] In certain embodiments, the pet food further comprises a phosphate or a derivative thereof. In certain embodiments, the phosphate is a pyrophosphate. In certain embodiments, the amount of the phosphate is from about 1 mM to about 1 M. In certain embodiments, the amount of the phosphate is about 10 mM.
[0018] In some embodiments, the pet food further comprises furan or its derivatives and phosphate or its derivatives. In some embodiments, the pet food further comprises one or more vitamins, minerals, antioxidants, thickeners or combinations thereof. In some embodiments, the pet food is drinking water. In some embodiments, the drinking water is packaged drinking water. In some embodiments, the animal is a feline.
[0019] In one aspect, the present disclosure provides a pet food for preventing and / or treating chronic kidney disease in an animal in need thereof, wherein the pet food comprises a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
[0020] In another aspect, the present disclosure provides a pet food for preventing and / or treating urinary tract diseases in an animal in need thereof, wherein the pet food comprises a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
[0021] In yet another aspect, the present disclosure provides a pet food for increasing water intake of an animal, wherein the pet food comprises milk protein and nucleotides or derivatives thereof.
[0022] Furthermore, in one aspect, the present disclosure provides a pet food for increasing hydration of an animal, wherein the pet food comprises a milk protein and a nucleotide or a derivative thereof.
[0023] Furthermore, in one aspect, the present disclosure provides a pet food for preventing and / or treating chronic kidney disease in an animal in need thereof, wherein the pet food comprises milk protein and nucleotides or derivatives thereof.
[0024] In another aspect, the present disclosure provides a pet food for preventing and / or treating urinary tract diseases in an animal in need thereof, wherein the pet food comprises milk protein and nucleotides or derivatives thereof.
[0025] In certain embodiments, the first amino acid is alanine, histidine, glycine, serine, tyrosine, or a mixture thereof. In certain embodiments, the second amino acid is proline, hydroxyproline, valine, threonine, lysine, or a mixture thereof. In certain embodiments, the first amino acid is histidine and the second amino acid is proline. In certain embodiments, the first amino acid is tyrosine and the second amino acid is lysine. In certain embodiments, the molar ratio of the first amino acid and the second amino acid is about 1:1. In certain embodiments, the molar ratio of the first amino acid and the second amino acid is about 1:1.3. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 1mM to about 1M. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 100mM. In certain embodiments, the amount of each of the first amino acid and the second amino acid is about 20mM to about 50mM.
[0026] In certain embodiments, the pet food contains no phosphates or derivatives thereof and / or contains no furans or derivatives thereof. In certain embodiments, the pet food further contains yeast extract.
[0027] In certain embodiments, the milk protein is casein or a derivative thereof. In certain embodiments, the amount of the milk protein is about 1 wt % to about 10 wt %. In certain embodiments, the amount of the milk protein is about 3 wt %.
[0028] In certain embodiments, the nucleotide or its derivative is AMP, UMP, GMP, IMP, CMP or a mixture thereof. In certain embodiments, the nucleotide or its derivative is obtained from a yeast extract. In certain embodiments, the yeast extract is a Kluyveromyces extract, a Torula extract or a Saccharomyces cerevisae extract. In certain embodiments, the amount of the nucleotide or its derivative is about 1 mM to about 100 mM. In certain embodiments, the amount of the nucleotide or its derivative is about 5 mM.
[0029] In some embodiments, the pet food further comprises furan or a derivative thereof. In some embodiments, the furan or a derivative thereof is a furanone. In some embodiments, the amount of furan or a derivative thereof is from about 1 ppm to about 100 ppm. In some embodiments, the amount of furan or a derivative thereof is about 4 ppm.
[0030] In certain embodiments, the pet food further comprises a phosphate or a derivative thereof. In certain embodiments, the phosphate is a pyrophosphate. In certain embodiments, the amount of the phosphate is from about 1 mM to about 1 M. In certain embodiments, the amount of the phosphate is about 10 mM.
[0031] In certain embodiments, the pet food further comprises one or more vitamins, minerals, antioxidants, thickeners or combinations thereof. In certain embodiments, the pet food is drinking water. In certain embodiments, the drinking water is packaged drinking water. In certain embodiments, the animal is a feline.
[0032] In another aspect, the present disclosure provides a flavor composition comprising:
[0033] a) a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor;
[0034] b) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, and a yeast extract;
[0035] c) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, yeast extract, minerals and phosphate;
[0036] d) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, yeast extract, minerals, phosphates and a thickener;
[0037] e) milk proteins and nucleotides or their derivatives;
[0038] f) milk proteins, nucleotides or their derivatives and furans or their derivatives; or
[0039] g) milk proteins, nucleotides or their derivatives, furans or their derivatives, and phosphates or their derivatives.
[0040] In some embodiments, the first amino acid is histidine and the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1 or about 1:1.3. In some embodiments, the milk protein is casein or a derivative thereof. In some embodiments, the nucleotide or a derivative thereof is AMP, UMP, GMP, IMP, CMP or a mixture thereof. In some embodiments, the nucleotide or a derivative thereof is GMP. In some embodiments, the nucleotide or a derivative thereof is IMP. In some embodiments, the nucleotide mixture comprises GMP and IMP. In some embodiments, the furan or a derivative thereof is furanone. In some embodiments, the phosphate is pyrophosphate. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 Shown are the mean differences in intake (g) of the flavor composition solution and water in Example 1, with 95.0% confidence intervals (Dunnett's test).
[0042] Figure 2 Shown are weighted mean intakes (95% confidence intervals based on Tukey's test) by flavor composition in Example 1. All means were significantly different.
[0043] Figure 3 Shown are the mean free water intake (g) for water baselines 1 and 2 in Example 2, with 95.0% confidence interval (difference 21.9 g, p-value 0.074).
[0044] Figure 4 Shown are mean daily free water intake for the flavor compositions tested in Example 2 and baseline water, with 95.0% confidence intervals using Dunnett's test.
[0045] Figure 5 The mean total water intake for the flavor compositions tested in Example 2 and water, with 95.0% confidence intervals, is shown as grams per kilogram of metabolic body weight (g / Kg BW). 0.711 ), using Dunnett's test.
[0046] Figure 6 Shown are the least square means for diet only or total caloric intake when cats were provided or not provided with Flavor Composition F supplementation.
[0047] Figure 7 Shown are the least square means of body weight when cats were provided two (2) diets with or without Flavor Composition F supplementation.
[0048] Figure 8 Shown are the least square means of sodium intake when cats were provided two (2) diets with or without Flavor Composition F supplementation.
[0049] Fig. 9 The volume of flavor composition F ingested by each cat on the two (2) diets is shown (in ml / kg / d).
[0050] Fig.10 The least square means of flavor composition F supplement intake volume according to diet are shown.
[0051] Fig.11 The least square means of the ingested volumes of water and flavor composition F when cats were provided with water and flavor composition F are shown.
[0052] Fig. 12AShown is the urine volume of cats provided with flavor composition F or control according to diet. Fig. 12B Shows Fig. 12A Details of the data described in .
[0053] Fig.13A and Fig. 13B The specific gravity of urine when flavor composition F was provided is shown.
[0054] Fig.14A Shown are the urine pH values of cats provided with Flavor Composition F or a control according to the diet. Fig. 14B Shows Fig.14A Details of the data described in .
[0055] Fig.15 Shown are box plots of relative supersaturation (RSS) MAP for cats provided flavor composition F or control according to diet.
[0056] Fig.16A Shown are the least square means of relative supersaturation of calcium oxalate (RSS CaOx) for cats provided with flavor composition F or control according to diet. Fig. 16B Shows Fig.16A Details of the data described in . Fig. 16C and Fig.16D The correlation between the intake of flavor component F and the RSS CaOx value is shown.
[0057] Fig.17 The percent change in relative supersaturation of calcium oxalate (RSS CaOx) after providing a dry diet for urinary tract diseases (labeled "Urodiet") with Flavor Composition F is shown and plotted against the amount of Flavor Composition F consumed.
[0058] Fig.18 The percent change in relative supersaturation of calcium oxalate (RSS CaOx) after providing a conventional diet versus Flavor Composition F is shown and plotted against the amount of Flavor Composition F consumed. DETAILED DESCRIPTION
[0059] To date, there remains a need for a flavor composition that can provide a desired level of enhanced and targeted palatability of water and / or water-based products. The present disclosure relates to a flavor composition that can be used to increase the total water intake of a cat. By increasing the water intake of a cat, the flavor composition of the present disclosure can be used to prevent and treat certain common kidney and urinary tract diseases, such as chronic kidney disease. For clarity of disclosure and not limitation, the specific embodiments are divided into the following subsections:
[0060] 1. Definition
[0061] 2. Flavor composition;
[0062] 3. Pet food;
[0063] 4. Formulation and delivery system; and
[0064] 5. Treatment methods.
[0065] 1. Definition
[0066] The terms used in this specification generally have their ordinary meanings in the art in the context of the present disclosure and in the specific context in which each term is used. Certain terms are discussed below or elsewhere in this specification to provide additional guidance to professionals when describing the methods and compositions of the present invention and how to make and use them.
[0067] As used herein, the words "a" or "an" when used with the term "comprising" in the claims and / or the specification may mean "one", but they also conform to the meaning of "one or more", "at least one" and / or "one or more than one".
[0068] The term "about" or "approximately" means within an acceptable error range for a particular value determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within three or more standard deviations. Alternatively, "about" can mean a range within up to 10%, more preferably up to 5%, more preferably up to 1% of a given value. Alternatively, particularly for biological systems or processes, the term can mean within an order of magnitude, preferably within five-fold, and more preferably within two-fold of a value.
[0069] As used herein, the terms "comprise(s)", "include(s)", "having", "has", "can", "contain(s)" and variations thereof are intended to serve as open transitional phrases, terms or words that do not exclude the possibility of additional actions or structures. The present disclosure also contemplates other embodiments "comprising", "consisting of", and "consisting essentially of", embodiments or elements described herein, whether or not explicitly stated.
[0070] As used herein, "taste" refers to the sensation caused by activation of receptor cells in the taste buds of a subject. In some embodiments, the taste can be selected from the group consisting of sweetness, sourness, saltiness, bitterness, kokumi, and umami. In some embodiments, "taste" can include free fatty acid taste. See, for example, Cartoni et al., Neuroscience, 30(25):8376-8382 (2010), the contents of which are incorporated herein by reference. In some embodiments, the taste of a subject is triggered by a "tastant". In some embodiments, the tastant can be a synthetic tastant. In some embodiments, the tastant is obtained or prepared from a natural source.
[0071] As used herein, "taste profile" refers to a combination of tastes, such as one or more of sweet, sour, salty, bitter, umami, kokumi, and free fatty acid tastes. In certain embodiments, the taste profile is produced by one or more tastants present in the composition at the same or different concentrations. In certain embodiments, the taste profile refers to the intensity of a taste or combination of tastes detected by a subject or any assay known in the art, such as sweet, sour, salty, bitter, umami, kokumi, and free fatty acid tastes. In certain embodiments, modifying, altering, or changing the combination of tastants in the taste profile can change the sensory experience of the subject.
[0072] As used herein, "flavor" refers to one or more sensory stimuli, such as one or more of taste (taste), smell (smell), touch (tactile) and temperature (heat) stimulation. In certain non-limiting embodiments, the sensory experience of a subject when exposed to a flavor can be classified as a unique experience of a specific flavor. For example, a flavor can be identified by a subject as (but not limited to) the flavor of flowers, citrus, berries, nuts, caramel, chocolate, pepper, smoked, cheese, meat, etc. As used herein, a flavor composition can be selected from a liquid, a solution, a dry powder, a spray, a paste, a suspension, and any combination thereof. The flavor can be a natural composition, an artificial composition, a natural equivalent, or any combination thereof.
[0073] As used herein, "flavor profile" refers to a combination of sensory stimuli, such as taste, e.g., sweet, sour, bitter, salty, umami, kokumi, and free fatty acid taste, and / or olfactory, tactile, and / or thermal stimuli. In certain embodiments, a flavor profile includes one or more flavors that contribute to a subject's sensory experience. In certain embodiments, modifying, altering, or changing the combination of stimuli in a flavor profile can change a subject's sensory experience.
[0074] As used herein, "admixing", e.g., "admixing the flavor composition of the present application or a combination thereof with water" or "admixing a compound with water" refers to the process of mixing or adding a flavor composition or a single component of a flavor composition to a finished product, or mixing with some or all of the components of a product, during the product formation process or some combination of these steps. When used in the context of mixing, the term "product" refers to a product or any component thereof. The mixing step may include a process selected from the steps of adding the flavor composition to the product, spraying the flavor composition on the product, dissolving the flavor composition on the product, suspending the product in the flavor composition, applying the flavor composition on the product, sticking the flavor composition on the product, encapsulating the product with the flavor composition, mixing the flavor composition with the product, and any combination thereof. The flavor composition may be a solution, a liquid, a dry powder, a spray, a paste, a suspension, and any combination thereof.
[0075] As used herein, "ppm" means parts per million, which is a weight relative parameter. One part per million is one microgram per gram, so that a component present in 10 ppm means that there are 10 micrograms of that particular component per 1 gram of the aggregate mixture.
[0076] As used herein, "palatability" can refer to the overall willingness of humans or non-human animals (e.g., companion animals) to eat a certain food. Improving the "palatability" of food can improve the enjoyment and acceptance of food by humans or non-human animals to ensure that humans or non-human animals eat a "healthy amount" of food. Reducing the "palatability" of food can lead to reducing the enjoyment and acceptance of food by humans or non-human animals. The "healthy amount" of the term food used herein refers to the amount of micronutrients, macronutrients, and calorie intake that enable humans or non-human animals to maintain or achieve their overall health, such as "Nutrient requirements of dogs and cats" (NRC, NRC. "Nutrient requirements of dogs and cats" National Research Council of the National Academy of Sciences (2006))). In some embodiments, "palatability" can refer to the relative preference of humans or non-human animals for a food relative to another food. For example, when a human or non-human animal shows a preference for one of two or more foods, the preferred food is more "palatable" and has "enhanced palatability". In certain embodiments, the relative palatability of a food compared to one or more other foods can be determined, for example, by a side-by-side, free choice comparison, such as by the relative consumption of the food, or other appropriate measurements indicating palatability preferences. Palatability can be determined by a standard test protocol in which animals have equal access to two foods, such as a test called a "two-bowl test" or a "versus test". This preference can come from any perception of the animal, but can be related to, among other things, taste, aftertaste, smell, mouthfeel and / or texture. In certain embodiments, palatability can be determined by a monadic test protocol described in Examples 1 and 2.
[0077] The term "pet food" or "pet food" or "finished pet food" refers to a product or composition for consumption by companion animals (e.g., cats, dogs, guinea pigs, rabbits, birds, and horses). For example, but not limited to, the companion animal may be a "domestic" dog, e.g., Canis lupus familiaris. In certain embodiments, the companion animal may be a "domestic" cat, e.g., Felis domesticus. "Pet food" or "pet food" includes any food, feed, treat, food supplement, liquid, beverage, snack, toy (chewable and / or edible toys), meal replacement, or meal substitute.
[0078] As used herein, "nutritionally complete" means that a pet food contains all known nutrients required by the intended recipient of the pet food, in appropriate amounts and proportions, such as based on the recommendations of an organization recognized or competent in the field of companion animal nutrition. Thus, such a food is capable of serving as the sole source of dietary intake to sustain life without the need for the addition of supplemental sources of nutrition.
[0079] As used herein, "flavor composition" refers to at least one compound or biologically acceptable salt thereof that modulates (including enhancing, increasing, strengthening, reducing, inhibiting or inducing) the taste, smell, flavor and / or texture of a natural or synthetic tastant, flavoring, taste profile, flavor profile and / or texture profile of an animal or human. In certain embodiments, the flavor composition comprises a combination of compounds or biologically acceptable salts thereof. In certain embodiments, the flavor composition comprises one or more excipients.
[0080] As used herein, the term "umami taste receptor" refers to a G protein coupled receptor (GPCR), such as a T1R1 / T1R3 GPCR. The umami taste receptor can be, for example, a cat, dog, human or non-human mammal umami taste receptor.
[0081] As used herein, the term "modulate" or "modify" refers to an increase or decrease in the amount, quality or effect of a specific activity of a receptor, and / or an increase or decrease in the expression, activity or function of a receptor. As used herein, "modulator" refers to any inhibitory or activating compound identified using computer simulation, in vitro and / or in vivo detection methods for, for example, agonists, antagonists, allosteric modulators and homologues thereof (including fragments, variants and mimetics).
[0082] As used herein, "inhibitor" or "antagonist" refers to a modulatory compound that decreases, reduces, blocks, prevents, delays activation, inactivates, desensitizes or downregulates the biological activity and / or expression of a receptor or pathway of interest. The term "antagonist" includes full antagonists, partial antagonists and neutral antagonists, as well as inverse agonists.
[0083] As used herein, "inducer," "activator," or "agonist" refers to a modulatory compound that increases, induces, stimulates, opens, activates, promotes, enhances activation, sensitizes, or upregulates a receptor or pathway of interest. The term "agonist" includes full agonists and partial agonists.
[0084] As used herein, "allosteric modulators" refer to "positive allosteric modulators" and "negative allosteric modulators." "Positive allosteric modulators" (also called "PAMs") refer to regulatory compounds that increase, induce, stimulate, open, activate, promote, enhance activation, sensitize, or upregulate a receptor or pathway of interest by binding of different compounds to the receptor. "Negative allosteric modulators" refer to regulatory compounds that decrease, reduce, block, prevent, delay activation, inactivate, desensitize, or downregulate the biological activity and / or expression of a receptor or pathway of interest by binding of different compounds to the receptor.
[0085] As used herein, the terms "nucleic acid molecule" and "nucleotide sequence" refer to a single-stranded or double-stranded covalently linked sequence of nucleotides, wherein the 3' and 5' ends of each nucleotide are linked by a phosphodiester bond. Nucleic acid molecules can include deoxyribonucleotide bases or ribonucleotide bases, and can be synthesized in vitro or isolated from natural sources.
[0086] The terms "polypeptide", "peptide", "amino acid sequence" and "protein" used interchangeably herein refer to molecules formed by the linkage of at least two amino acids. The linkage between one amino acid residue and the next is an amide bond, sometimes also referred to as a peptide bond. Polypeptides can be obtained by suitable methods known in the art, including isolation from natural sources, expression in a recombinant expression system, chemical synthesis or enzymatic synthesis. The term can be applied to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0087] As used herein, the term "amino acid" may be naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are amino acids encoded by the genetic code, as well as amino acids that are subsequently modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs and derivatives may refer to compounds having the same basic chemical structure as naturally occurring amino acids, i.e., a carbon bonded to a hydrogen, carboxyl, amino, and R groups, such as homoserine, norleucine, methionine sulfoxide, and methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to compounds having a structure that is different from the general chemical structure of an amino acid but functions in a manner similar to naturally occurring amino acids. Non-limiting examples of amino acids include tryptophan, phenylalanine, histidine, glycine, cysteine, alanine, tyrosine, serine, methionine, asparagine, leucine, asparagine, threonine, isoleucine, proline, glutamic acid, aspartic acid, hydroxyproline, arginine, cystine, glutamine, lysine, valine, ornithine, taurine, and combinations thereof.
[0088] As used herein, the term "amino acid source" refers to a substance containing amino acids. In certain non-limiting embodiments, the amino acid source may include or be derived from plant protein, animal protein, single cell organism protein, and free amino acids.
[0089] As used herein, the term "animal protein" refers to protein from animal sources. Such animal proteins include, for example, but not limited to, meat (e.g., pork, beef, or veal), poultry (e.g., chicken), fish, organs (e.g., liver, spleen, or heart), viscera (e.g., viscera of chicken or pork), and combinations thereof. As animal protein, animal protein may be selected from, for example, but not limited to, poultry, beef, chicken, chicken meal, mutton, mutton meal, dried egg, fish, fish meal, meat and bone meal, meat by-products, meat meal, turkey, plasma, or bone marrow.
[0090] As used herein, unless otherwise indicated, the term "nucleotide" refers to a 5' nucleotide, i.e., a nucleotide having a phosphate group at the 5' position of the ribose. "Nucleotide" should be understood as a subunit of a deoxyribonucleic acid ("DNA") or a ribonucleic acid ("RNA"). Such 5' nucleotides can be obtained, for example, but not limited to, by treating the raw material with a 5' nucleotidase and / or a phosphatase. In certain embodiments, the 5' nucleotides encompassed by the present disclosure can be selected from the group consisting of: adenosine monophosphate (AMP), guanosine monophosphate (GMP), inosine monophosphate (IMP), uridine monophosphate (UMP), cytidine monophosphate (CMP), thymidine monophosphate (TMP), xanthosine monophosphate (xanthosine monophosphate) (XMP) and a mixture of two or more thereof. For example, but not limited to, the nucleotide can be AMP, GMP, IMP, or a mixture thereof. In certain exemplary embodiments, the nucleotide can be a single GMP, a single IMP, or a mixture thereof.
[0091] As used herein, unless otherwise indicated, the term "nucleotide source" refers to any source, particularly a natural source, that is natural, processed or provided as a raw material containing nucleotides as defined above. For example, but not limited to, the nucleotide source encompassed by the present disclosure may be a hydrolyzed nucleotide; for example, a partially or completely hydrolyzed nucleotide. In certain embodiments, the nucleotide source encompassed by the present disclosure may be a biological extract. In certain embodiments, the biological extract may be a bacterial extract or a yeast extract. In certain embodiments, the nucleotide source is a yeast extract. In certain embodiments, the yeast of the nucleotide source may be Kluyveromyces or Saccharomyces cerevisiae. In certain embodiments, the yeast of the nucleotide source may be Torula (Cyberlindnera jadinii). Other examples of nucleotide sources may include petMOD commercialized by PROSOL SpA. TM and / or petMOD TM S is a source of feed material. Quality control of yeast extract nucleotides can be achieved by any method known in the art, such as ion-pair high performance liquid chromatography.
[0092] As used herein, the term "derivative" refers to a compound that is derived from some other compound and retains its general structure. For example, but not limited to, chloroform is a derivative of methane.
[0093] The term "enantiomers" refers to a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture or racemate. Where appropriate, the term is used to refer to a racemic mixture.
[0094] The term "enantiomerically pure" refers to a sample consisting of a single enantiomer within the limits of detection.
[0095] The term "diastereomer" refers to stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is assigned according to the Cahn-Ingold-Prelog R—S system. When a compound is enantiomerically pure, the stereochemistry at each chiral carbon can be assigned with R or S. Resolved compounds whose absolute configuration is unknown can be assigned as (+) or (-) based on the direction (right-handed or left-handed) in which they rotate plane polarized light at the wavelength of the sodium D line.
[0096] The term "isomer" refers to different compounds having the same molecular formula but different arrangements and configurations of the atoms. Additionally, as used herein, the term "stereoisomer" refers to any of the various stereoisomeric configurations that can exist for a given compound of the disclosed subject matter, and includes geometric isomers. It is understood that substituents can be attached to chiral centers at carbon atoms. Additionally, as used herein, the term "constitutional isomers" refers to different compounds having the same number and type of atoms but with different ways of connecting the atoms.
[0097] 2. Flavor Composition
[0098] In certain embodiments, the present disclosure provides flavor compositions with improved palatability. For example, but not limited to, the flavor compositions disclosed herein can improve umami taste.
[0099] In some embodiments, the flavor composition is combined with an umami receptor. Umami receptors (e.g., T1R1 / T1R3) detect food molecules that can trigger taste qualities and characteristics (e.g., improved palatability or umami taste). The detection of molecules that trigger taste qualities by umami receptors increases the willingness of animals (e.g., cats or dogs) to eat specific foods. Additional information about the properties of umami receptors can be found in international patent applications PCT / EP2013 / 072794 and PCT / US2015 / 065046, which are incorporated herein by reference in their entirety. In some embodiments, the umami receptor is a cat T1R1 protein. In some embodiments, the T1R1 protein comprises or consists of the amino acid sequence listed in SEQ ID NO:1. In some embodiments, the umami receptor is a cat T1R3 protein. In some embodiments, the T1R3 protein comprises or consists of the amino acid sequence listed in SEQ ID NO:2. SEQ ID NOs:1-2 are provided as follows.
[0100] MSLPAAHLVGLQLSLSCCWALSCHSTETSADFSLPGDYLLAGLFPLHSDCPGVRHRPTVT
[0101] LCDRPDSFNGHGYHLFQAMRFGIEEINNSTALLPNVTLGYQLYDVCSESANVYATLNVLS
[0102] LLGTHHVEIRADPSHYSPAALAVIGPDTTNHAATTAALLSPFLVPLISYEASSVTLGVKR
[0103] HYPSFLRTIPSDKHQVEAMVLLLQSFGWVWISVVGSDGDYGQLGVQALEEQATQQGICVA
[0104] FKDIIPFSARPGDERMQGIMHHLARARTTVVVVFSSRQLARVFFESVVLANLTAKVWIAS
[0105] EDWAISRHISNVPGIQGIGTVLGVAIQQRLVPGLKEFEEAYVQADKGAPGPCSRTSECSS
[0106] NQLCRECRAFTAEQMPTLGAFSMSSAYNAYRAVYAVAHGLHQLLGCASGACSRDRVYPWQ
[0107] LLEQIRKVNFLLHKDTVRFNDNGDPLSGYDIIAWDWSGPKWNFRVIGSSMWPPVQLDINK
[0108] TKIRWHGKDNQVPKSVCSSDCLEGHQRVISGFYHCCFECVPCEAGSFLNKSDLHSCQPCG
[0109] KEEWAPAGSETCFPRTVVFLTWHETISWVLLAANTLLLLLVTGTAGLFAWHLDTPVVKSA
[0110] GGRLCFFMLGSLAGGSCGLYGFFGEPTLPTCLLRQSLLALGFAIFLSCLTIRSFQLVFIF
[0111] KFSAKVPTFYRAWVQNHGPGLFVVISSMAQLLICLTWLAVWTPLPTREYQRFPQLVVLDC
[0112] TEANSPGFMLAFAYNGLLSVSAFACSYLGKDLPENYNEAKCVTFSLLLNFVSWIAFFTTA
[0113] SVYQGKYLPAVNVLAALSSLSGGFSGYFLPKCYVILCRPDLNSTEHFQASIQEYTRRCGS
[0114] T(SEQ ID NO:1)
[0115] MPGLALLGLTALLGLTALLDHGEGATSCLSQQLRMQGDYVLGGLFPLGSAEGTGLGDGLQ
[0116] PNATVCTRFSSLGLLWALAVKMAVEEINNGSALLPGLHLGYDLFDTCSEPMVAMKPSLVF
[0117] MAKAGSCSIAAYCNYTQYQPRVLAVIGPHSSELALVTGKFFSFFLVPQVSYGASTDRLSN
[0118] REIFPSFFRTVPSDQVQVAAMVELLQELGWNWVAAVGSDDEYGRQGLSLFSGLASARGIC
[0119] IAHEGLVPLPPGSLRLGALQGLLRQVNQSSVQVVVLFSSAHAARTLFSYSIRCKLSPKVW
[0120] VASEAWLTSDLVMTLPGMPGVGTVLGFLQQGAPMPEFPSYVRTRLALAADPAFCASLDAE
[0121] QPGLEEHVVGPRCPQCDHVTLENLSAGLLHHQTFAAYAAVYGVAQALHNTLRCNASGCPR
[0122] REPVRPWQLLENMYNVSFRARGLALQFDASGNVNVDYDLKLWVWQDPTPELRTVGTFKGR
[0123] LELWRSQMCWHTPGKQQPVSQCSRQCKEGQVRRVKGFHSCCYDCVDCKAGSYQRNPDDLL
[0124] CTQCDQDQWSPDRSTRCFARKPMFLAWGEPAVLLLLALLALALGLALAALGLFLWHSDSP
[0125] LVQASGGPRACFGLACLGLVCLSVLLFPGQPGPASCLAQQPLFHLPLTGCLSTLFLQAAE
[0126] IFVGSELPPSWAEKMRGRLRGPWAWLVVLLAMLAEAALCAWYLVAFPPEVVTDWRVLPTE
[0127] ALVHCHVHSWISFGLVHATNAMLAFLCFLGTFLVQSRPGRYNGARGLTFAMLAYFITWIS
[0128] FVPLFANVHVAYQPAVQMGTILLCALGILATFHLPKCYLLLQRPELNTPEFFLEDNARAQ
[0129] GSSWGQGRGESGQKQVTPDPVTSPQ(SEQ ID NO:2)
[0130] In certain embodiments, the flavor composition of the present disclosure comprises one or more amino acids or derivatives thereof. In certain embodiments, the flavor composition comprises a first amino acid or a derivative thereof. In certain embodiments, the first amino acid can activate an umami receptor. In certain embodiments, the first amino acid is an agonist of an umami receptor. In certain embodiments, the first amino acid is alanine, histidine, glycine, serine, tyrosine, or a mixture thereof. In certain embodiments, the first amino acid is histidine. In certain embodiments, the first amino acid is alanine. In certain embodiments, the first amino acid is glycine. In certain embodiments, the first amino acid is serine. In certain embodiments, the first amino acid is tyrosine.
[0131] In some embodiments, the flavor composition comprises a second amino acid or a derivative thereof. In some embodiments, the second amino acid cannot activate an umami taste receptor. In some embodiments, the second amino acid is an allosteric modulator of an umami taste receptor. In some embodiments, the second amino acid is proline, hydroxyproline, valine, threonine, lysine, or a mixture thereof. In some embodiments, the second amino acid is proline. In some embodiments, the second amino acid is hydroxyproline. In some embodiments, the second amino acid is valine. In some embodiments, the second amino acid is threonine. In some embodiments, the second amino acid is lysine.
[0132] In some embodiments, the flavor composition comprises a first amino acid and a second amino acid. In some embodiments, the first amino acid is histidine and the second amino acid is proline. In some embodiments, the first amino acid and the second amino acid may be present in a certain ratio. In some embodiments, the molar ratio of the first amino acid and the second amino acid in the flavor composition may be between about 1:100 and about 1:1, between about 1:100 and about 1:2, between about 1:100 and about 1:5, between about 1:100 and about 1:10, between about 1:100 and about 1:20, between about 1:50 and about 1:1, between about 1:50 and about 1:2, between about 1:50 and about 1:5, or between about 1:50 and about 1:10 (in moles). In certain embodiments, the ratio may be between about 1:30 and about 1:1, about 1:30 and about 1:2, about 1:30 and about 1:5, about 1:30 and about 1:10, about 1:20 and about 1:1, about 1:20 and about 1:2, or about 1:20 and about 1:5. In certain embodiments, the molar ratio may be between about 1:15 and about 1:1, about 1:15 and about 1:2, about 1:15 and about 1:5, about 1:10 and about 1:1, about 1:10 and about 1:2, about 1:10 and about 1:5, about 1:5 and about 1:1, or about 1:5 and about 1:2, such as about 1:12 or about 1:6. In certain embodiments, the first amino acid and the second amino acid can be present in a molar ratio of about 50: 1, about 30: 1, about 10: 1, about 5: 1, about 3: 1, about 1: 1, about 0.02: 1, or about 0.015: 1. In certain embodiments, the first amino acid and the second amino acid can be present in a molar ratio of about 0.5: 1, about 0.6: 1, about 0.7: 1, about 0.8: 1, about 0.9: 1, about 0.71: 1, about 0.72: 1, about 0.73: 1, about 0.74: 1, about 0.75: 1, about 0.76: 1, about 0.77: 1, about 0.78: 1, or about 0.79: 1. In certain embodiments, the first amino acid and the second amino acid may be present in a molar ratio of about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, or about 1:1.9. In certain embodiments, the first amino acid and the second amino acid may be present in a molar ratio of about 1:1. In certain embodiments, the first amino acid and the second amino acid may be present in a molar ratio of about 1:1.
[0133] In some embodiments, the flavor composition includes milk protein, its derivative or its salt. In some embodiments, the milk protein is casein or its salt. Casein accounts for about 80% (29.5g / L) of the total protein in milk. Casein is mainly bound to phosphate and includes a calcium phosphate-micelle complex. Casein includes a heterogeneous family consisting of 4 main components, including α-(αs1- and αs2-casein) casein, β-casein, γ-casein and κ-casein. In some embodiments, the flavor composition comprises casein. In some embodiments, the flavor composition comprises calcium caseinate. In some embodiments, the flavor composition comprises sodium caseinate. In some embodiments, the milk protein comprises casein hydrolysate. Casein hydrolysate is prepared by hydrolyzing a casein substrate (e.g., sodium caseinate). In some embodiments, casein hydrolysate is prepared by enzymatic hydrolysis. In some embodiments, casein hydrolysate is prepared by acid hydrolysis. In some embodiments, the flavor composition does not include milk protein, its derivatives or salts thereof. In some embodiments, the flavor composition includes nucleotides. As used herein, the term "nucleotide" refers to an organic compound having a nitrogenous purine or pyrimidine base and a phosphate group connected to a sugar (ribose or deoxyribose). Non-limiting examples of nucleotides include guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), inosine monophosphate (IMP), inosine diphosphate (IDP), inosine triphosphate (ITP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP) and xanthosine monophosphate (XMP), xanthosine diphosphate (XDP) and xanthosine triphosphate (XTP). In certain embodiments, the nucleotide is GMP. In certain embodiments, the nucleotide is obtained from a yeast extract. In certain embodiments, the yeast extract may be a Kluyveromyces extract, a Torula extract, or a Saccharomyces cerevisiae extract. In certain embodiments, the flavor composition comprises a nucleotide derivative. Additional information and examples of nucleotide derivatives encompassed by the present disclosure can be found in International Patent Application PCT / US2015 / 065067, which is incorporated herein by reference in its entirety. In certain embodiments, the flavor composition does not comprise a nucleotide or a derivative thereof.
[0134] Additionally or alternatively, the flavor composition comprises a yeast extract. In some embodiments, the yeast extract can be obtained from different types of yeast. For example, but not limited to, the yeast extract can be obtained from Saccharomyces, Pichia, Kluyveromyces, Hansenula, Candida, and Torula. In some embodiments, the yeast extract is obtained from Saccharomyces yeast. In some embodiments, the yeast extract is obtained from Kluyveromyces. In some embodiments, the yeast extract is obtained from Torula. In some embodiments, the flavor composition comprises furan or a derivative thereof. Furan is a heterocyclic organic compound having a five-membered aromatic ring consisting of four carbon atoms and one oxygen atom. Compounds containing such rings are also referred to as furans. Non-limiting examples of furan derivatives include furanone, methoxyfuranone, furazolidone, nifuratel, and furaltadone. In certain embodiments, the flavor composition comprises furanone. In certain embodiments, the flavor composition does not comprise nucleotides or derivatives thereof.
[0135] In certain embodiments, the flavor composition comprises a phosphate. As used herein, "phosphate" is a salt formally based on a phosphorus (V) oxoacid, particularly a salt of phosphorus (V) acid (H3PO4). There are also a large number of polymeric phosphates containing P-O-P bridges. In certain embodiments, the phosphate may be a linear polyphosphate, a cyclic polyphosphate, a cross-linked polyphosphate, or a superphosphate. In certain embodiments, the phosphate is a pyrophosphate (PPi). In certain embodiments, the flavor composition does not comprise a nucleotide or a derivative thereof.
[0136] In certain embodiments, the flavor composition comprises vitamins. Non-limiting examples of vitamins include vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B6 (pyridoxine), vitamin B12 (cyanocobalamin), pantothenic acid, biotin, folic acid, choline, and carnitine.
[0137] In some embodiments, the flavor composition comprises minerals. For example, but not limited to, minerals encompassed by the present disclosure include calcium, phosphorus, potassium, sodium, chloride, magnesium, iron, zinc, iodine, chromium, copper, fluoride, molybdenum, manganese and selenium. In some embodiments, the mineral is calcium chloride.
[0138] In some embodiments, the flavor composition comprises a thickener. For example, but not limited to, the thickeners encompassed by the present disclosure include starch and derivatives thereof from corn, wheat, rice, potato, cassava. Other examples of thickeners encompassed by the present disclosure include carrageenan, xanthan gum, guar gum, locust bean and carboxymethyl cellulose. In some embodiments, the thickener is xanthan gum.
[0139] In certain embodiments, the flavor composition comprises an antioxidant. Non-limiting examples of antioxidants include beta-carotene, catechins, copper, cryptoxanthin, flavonoids, indoles, isoflavonoids, lignans, lutein, lycopene, and polyphenols.
[0140] In certain embodiments, the compounds (e.g., the first amino acid and the second amino acid) of the flavor composition may include stereoisomers, enantiomers, diastereomers, or racemates of the compounds and molecules disclosed herein. The compounds of the present disclosure may contain one or more asymmetric centers, and thus may produce enantiomers, diastereomers, and other stereoisomeric forms, which may be defined as (R)- or (S)- in terms of absolute stereochemistry. The present disclosure is intended to include all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituents may have a cis or trans configuration. All tautomeric forms should also be included.
[0141] In some embodiments, the compound of the flavor composition may include a salt form of the compound. For example, but not limited to, the salt form includes acetate, formate, TFA (trifluoroacetic acid) salt or sulfonate. In some embodiments, the compound salt includes a salt that is bound to a cation (+) (for example, but not limited to Al) via an ionic bond. 3+ , Ca 2+ 、Na + , K + , Cu 2+ , H + , Fe 3+ Mg 2+ NH 4 + and H3O + ) combined with anions (-) (such as but not limited to Cl-, O 2- 、CO3 2- , HCO 3- OH - 、NO3 - PO43- 、SO4 2- 、CH3COO - HCOO - and C2O4 2- In certain embodiments, the compound salt comprises a cation (+) bound to an anion (-) via an ionic bond.
[0142] In certain embodiments, the compounds of the flavor composition can be produced using standard chemical synthesis processes. In certain embodiments, the chemical synthesis process provides a compound with a purity of at least 99.999%, or at least 99%, or at least 95%, or at least 90%, or at least 85%, or at least 80%. In certain embodiments, the compound can be prepared using standard hydrolysis processes (e.g., hydrolysis processes using acids, enzymes, or a combination of acids and enzymes).
[0143] In some embodiments, the compounds of the flavor composition can also be generated under food preparation conditions, such as during the production of pet food. For example, but not limited to, the compounds of the present disclosure can be generated from precursor compounds present in pet food during hot food processing (e.g., sterilization, cooking and / or extrusion). In some embodiments, the flavor composition can be mixed with a liquid (e.g., drinking water) or generated in a liquid. Alternatively or additionally, the flavor composition can be mixed with a liquid (e.g., drinking water) or dissolved in a liquid.
[0144] 2.1. Exemplary Flavor Compositions
[0145] In some embodiments, the flavor composition comprises a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the flavor composition does not contain milk protein. In some embodiments, the flavor composition does not contain phosphates or derivatives thereof. In some embodiments, the flavor composition does not contain furans or derivatives thereof.
[0146] In some embodiments, the flavor composition is composed of a first amino acid that can activate an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.
[0147] In some embodiments, the flavor composition is composed of a first amino acid capable of activating an umami taste receptor, a second amino acid that cannot activate an umami taste receptor, a yeast extract, a mineral, and a phosphate. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the mineral is calcium chloride. In some embodiments, the phosphate is pyrophosphate.
[0148] In some embodiments, the flavor composition is composed of a first amino acid that can activate an umami receptor, a second amino acid that cannot activate an umami receptor, a yeast extract, a mineral, a phosphate, and a thickener. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the mineral is calcium chloride. In some embodiments, the phosphate is pyrophosphate. In some embodiments, the thickener is xanthan gum.
[0149] In some embodiments, the flavor composition comprises a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3. In some embodiments, the flavor composition does not contain milk protein. In some embodiments, the flavor composition does not contain phosphate or its derivatives. In some embodiments, the flavor composition does not contain furan or its derivatives.
[0150] In some embodiments, the flavor composition comprises a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3.
[0151] In some embodiments, the flavor composition comprises a first amino acid capable of activating an umami taste receptor, a second amino acid that cannot activate an umami taste receptor, and a yeast extract. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3.
[0152] In some embodiments, the flavor composition comprises milk protein and nucleotides or derivatives thereof. In some embodiments, the milk protein is casein hydrolysate. In some embodiments, the nucleotide is GMP. In some embodiments, the flavor composition further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the flavor composition further comprises phosphate. In some embodiments, the phosphate is pyrophosphate.
[0153] In some embodiments, the flavor composition comprises milk protein and nucleotides or derivatives thereof. In some embodiments, the milk protein is casein hydrolysate. In some embodiments, the nucleotide is IMP. In some embodiments, the flavor composition further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the flavor composition further comprises phosphate. In some embodiments, the phosphate is pyrophosphate.
[0154] In some embodiments, the flavor composition comprises milk protein and a nucleotide mixture. In some embodiments, the milk protein is casein hydrolysate. In some embodiments, the nucleotide mixture comprises GMP and IMP or consists of GMP and IMP. In some embodiments, the flavor composition further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the flavor composition further comprises phosphate. In some embodiments, the phosphate is pyrophosphate.
[0155] 3. Pet Food
[0156] The present disclosure provides pet foods comprising the flavor compositions disclosed herein (see Section 2). In certain embodiments, the flavor compositions are added directly to pet foods. The flavor compositions disclosed herein provide unexpected flavors and impart sensory experiences such as umami. The flavor compositions disclosed herein can be added before, during, or after the formulation, processing, or packaging of pet foods.
[0157] Non-limiting examples of suitable pet foods include wet foods, dry foods, moist foods, pet food supplements (eg, vitamins), pet beverage products, treats and snacks, and the pet food categories described herein.
[0158] In some embodiments, the pet food is a pet beverage product. In some embodiments, the pet beverage product is drinking water. "Drinking water" is water that is safe to drink or use for food preparation. In some embodiments, the drinking water can be tap water. In some embodiments, the pH of the drinking water is about 5.0 to about 8.0, about 5.0 to about 7.5, about 5.0 to about 7.0, about 5.0 to about 6.5, about 5.0 to about 6.0, about 6.0 to about 8.0, about 6.0 to about 7.5, about 6.0 to about 7.0, about 6.0 to about 6.9, about 6.0 to about 6.8, about 6.0 to about 6.7, about 6.0 to about 6.6, about 6.0 to about 6.5, about 6.1 to about 6.5, about 6.2 to about From about 7.0 to about 7.9, from about 7.0 to about 7.8, from about 7.0 to about 7.7, from about 7.0 to about 7.6, from about 7.0 to about 7.5, from about 7.1 to about 7.5, from about 7.2 to about 7.5, from about 7.3 to about 7.5, from about 7.4 to about 7.5, from about 7.2 to about 7.5, or from about 7.2 to about 7.4.
[0159] In certain embodiments, the pH of the drinking water is about 7.0 to about 7.1. In certain embodiments, the pH of the drinking water is about 7.03. In certain embodiments, the pH of the drinking water is about 7.13.
[0160] In some embodiments, the pH of the drinking water is about 6.8 to about 7.0. In some embodiments, the pH of the drinking water is about 6.87. In some embodiments, the pH of the drinking water is about 6.86. In some embodiments, the pH of the drinking water is about 6.90.
[0161] In some embodiments, the pH of the drinking water is about 7.5 to about 7.8. In some embodiments, the pH of the drinking water is about 7.79. In some embodiments, the pH of the drinking water is about 7.77. In some embodiments, the pH of the drinking water is about 7.75. In some embodiments, the pH of the drinking water is about 7.74.
[0162] In certain embodiments, the flavor composition of the present disclosure is present in the pet food in an amount sufficient to modulate, activate and / or enhance the umami taste receptors. For example, but not limited to, the flavor composition may be present in the pet food in an amount of about 1 nM to about 1 M, about 1 μM to about 1 M, about 1 mM to about 1 M, about 10 mM to about 1 M, about 100 mM to about 1 M, about 250 mM to about 1 M, about 500 mM to about 1 M, about 750 mM to about 1 M, about 0.001 μM to about 1 M, about 0.001 μM to about 750 mM ... 1 μM to about 500 mM, about 0.001 μM to about 250 mM, about 0.001 μM to about 100 mM, about 0.001 μM to about 50 mM, about 0.001 μM to about 25 mM, about 0.001 μM to about 10 mM, about 0.001 μM to about 1 mM, about 0.001 μM to about 100 μM or about 0.001 μM to about 10 μM, and values therebetween.
[0163] In certain embodiments, the flavor composition is present in the pet food in an amount of about 0.001 ppm to about 10,000 ppm. For example, but not limited to, the flavor composition may be present in an amount of about 0.001 ppm to about 7,500 ppm, about 0.001 ppm to about 5,000 ppm, about 0.001 ppm to about 2,500 ppm, about 0.001 ppm to about 1,000 ppm, about 0.001 ppm to about 750 ppm, about 0.001 ppm to about 500 ppm, about 0.001 ppm to about 250 ppm, about 0.001 ppm to about 150 ppm, about 0.001 ppm to about 2,500 ppm to about 100 ppm, about 0.001 ppm to about 75 ppm, about 0.001 ppm to about 50 ppm, about 0.001 ppm to about 25 ppm, about 0.001 ppm to about 15 ppm, about 0.001 ppm to about 10 ppm, about 0.001 ppm to about 5 ppm, about 0.001 ppm to about 4 ppm, about 0.001 ppm to about 3 ppm, about 0.001 ppm to about 2 ppm, about 0.001 ppm to about 1 ppm, about 0.01 ppm to about to about 10,000 ppm, about 0.01 ppm to about 7,500 ppm, about 0.01 ppm to about 5,000 ppm, about 0.01 ppm to about 2,500 ppm, about 0.1 ppm to 1,000 ppm, about 1 ppm to 1,000 ppm, about 2 ppm to about 1,000 ppm, about 3 ppm to about 1,000 ppm, about 4 ppm to about 1,000 ppm, about 5 ppm to about 1,000 ppm, about 10 ppm to about 1,000 ppm, From about 15 ppm to about 1,000 ppm, from about 25 ppm to about 1,000 ppm, from about 50 ppm to about 1,000 ppm, from about 75 ppm to about 1,000 ppm, from about 100 ppm to about 1,000 ppm, from about 150 ppm to about 1,000 ppm, from about 250 ppm to about 1,000 ppm, from about 250 ppm to about 1,000 ppm, from about 500 ppm to about 1,000 ppm, or from about 750 ppm to about 1,000 ppm, and values therebetween.
[0164] In certain embodiments, the flavor composition is present in the pet food at an amount greater than about 0.001 ppm, greater than about 0.01 ppm, greater than about 0.1 ppm, greater than about 1 ppm, greater than about 2 ppm, greater than about 3 ppm, greater than about 4 ppm, greater than about 5 ppm, greater than about 10 ppm, greater than about 25 ppm, greater than about 50 ppm, greater than about 75 ppm, greater than about 100 ppm, greater than about 250 ppm, greater than about 500 ppm, greater than about 750 ppm, greater than about 1,000 ppm, greater than about 2,500 ppm, greater than about 5,000 ppm, greater than about 7,500 ppm, or greater than about 10,000 ppm, and values therebetween.
[0165] In certain embodiments, the flavor composition is mixed with a food (e.g., drinking water), wherein the content of the flavor composition is about 0.0001 to about 10% weight / weight (w / w) of the food. For example, but not limited to, the content of the flavor composition can be about 0.0001% to about 10%, about 0.0001% to about 1%, about 0.0001% to about 0.1%, about 0.0001% to about 0.01%, about 0.0001% to about 0.001%, about 0.001% to about 10%, about 0.001% to about 1%, about 0.01% to about 1%, or about 0.1% to about 1%, and values therebetween.
[0166] In certain embodiments, when the flavor composition comprises an amino acid or a derivative thereof, the amino acid or a derivative thereof may be present in the pet food in an amount of about 1 mM to about 1 M, or about 250 mM to about 1 M, or about 5 mM to about 500 mM, or about 10 mM to about 100 mM, or about 15 mM to about 50 mM, or about 20 mM to about 40 mM. In certain embodiments, the amino acid or a derivative thereof may be present in an amount of less than about 1 M, less than about 200 mM, less than about 100 mM, less than about 50 mM, less than about 20 mM, or less than about 10 mM of the pet food. In certain embodiments, the amino acid or a derivative thereof may be present in an amount of about 200 mM of the pet food. In certain embodiments, the amino acid or a derivative thereof may be present in an amount of about 100 mM of the pet food.
[0167] In certain embodiments, when the flavor composition comprises milk protein, its derivative or its salt, the content of milk protein, its derivative or its salt in the pet food can be about 0.0001 to about 10% weight / weight (w / w) of the pet food. In certain embodiments, the content of milk protein, its derivative or its salt can be about 0.0001% w / w to about 10% w / w, about 0.0001% w / w to about 1% w / w, about 0.0001% w / w to about 0.1% w / w, about 0.0001% w / w to about 0.01% w / w, about 0.0001% w / w to about 0.001% w / w, about 0.001% w / w to about 0.001% w / w, about 0.001% w / w to about 10% w / w, about 0.001% w / w to about 1% w / w, about 0.01% w / w to about 1% w / w, or about 0.1% w / w to about 1% w / w, and values therebetween. In certain embodiments, the amount of milk protein, its derivative or salt thereof in the pet food is from about 1% w / w to about 5% w / w, from about 1.5% w / w to about 5% w / w, from about 2% w / w to about 5% w / w, from about 2.5% w / w to about 5% w / w, from about 3% w / w to about 5% w / w, from about 3.5% to about 5% w / w, from about 4% to about 5% w / w, from about 4.5% w / w to about 5% w / w, and values therebetween. In certain embodiments, the content of milk protein, its derivative or salt thereof in the pet food is about 1% w / w to about 5% w / w, about 1% w / w to about 4.5% w / w, about 1% w / w to about 4% w / w, about 1% w / w to about 3.5% w / w, about 1% w / w to about 3% w / w, about 1% w / w to about 2.5% w / w, about 1% w / w to about 2% w / w, about 1% w / w to about 1.5% w / w, about 2% w / w to about 4% w / w, about 2.5% w / w to about 3.5% w / w, and values therebetween. In certain embodiments, the content of milk protein, its derivative or salt thereof is about 3% w / w.
[0168] In certain embodiments, when the flavor composition comprises milk protein, its derivative or its salt, the content of milk protein, its derivative or its salt in the pet food can be about 0.0001 to about 10% weight / volume (w / v) of the pet food. In certain embodiments, the content of milk protein, its derivative or its salt can be about 0.0001% w / v to about 10% w / v, about 0.0001% w / v to about 1% w / v, about 0.0001% w / v to about 0.1% w / v, about 0.0001% w / v to about 0.01% w / v, about 0.0001% w / v to about 0.001% w / v, about 0.001% w / v to about 0.001% w / v, about 0.001% w / v to about 10% w / v, about 0.001% w / v to about 1% w / v, about 0.01% w / v to about 1% w / v, or about 0.1% w / v to about 1% w / v, and values therebetween. In certain embodiments, the amount of milk protein, its derivative or salt thereof in the pet food is from about 1% w / v to about 5% w / v, from about 1.5% w / v to about 5% w / v, from about 2% w / v to about 5% w / v, from about 2.5% w / v to about 5% w / v, from about 3% w / v to about 5% w / v, from about 3.5% w / v to about 5% w / v, from about 4% to about 5% w / v, from about 4.5% w / v to about 5% w / v, and values therebetween. In certain embodiments, the content of milk protein, its derivative or salt thereof in pet food is about 1% w / v to about 5% w / v, about 1% w / v to about 4.5% w / v, about 1% w / v to about 4% w / v, about 1% w / v to about 3.5% w / v, about 1% w / v to about 3% w / v, about 1% w / v to about 2.5% w / v, about 1% w / v to about 2% w / v, about 1% w / v to about 1.5% w / v, about 2% w / v to about 4% w / v, about 2.5% w / v to about 3.5% w / v, and values therebetween. In certain embodiments, the content of milk protein, its derivative or salt thereof is about 3% w / v.
[0169] In certain embodiments, when the flavor composition comprises nucleotides or derivatives thereof, the content of the nucleotides or derivatives thereof in the pet food may be from about 1 mM to about 1 M of the pet food, or from about 250 mM to about 1 M, or from about 5 mM to about 500 mM, or from about 10 mM to about 100 mM, or from about 15 mM to about 50 mM, or from about 20 mM to about 40 mM. In certain embodiments, the content of the nucleotides or derivatives thereof may be less than about 1 M, less than about 200 mM, less than about 100 mM, less than about 50 mM, less than about 20 mM, or less than about 10 mM of the pet food. In certain embodiments, the nucleotides or derivatives thereof may be about 5 mM of the pet food.
[0170] In certain embodiments, when the flavor composition comprises furan or its derivatives, the furan or its derivatives in the pet food may be present in an amount greater than about 0.001 ppm, greater than about 0.01 ppm, greater than about 0.1 ppm, greater than about 1 ppm, greater than about 2 ppm, greater than about 3 ppm, greater than about 4 ppm, greater than about 5 ppm, greater than about 10 ppm, greater than about 25 ppm, greater than about 50 ppm, greater than about 75 ppm, greater than about 100 ppm, greater than about 250 ppm, greater than about 500 ppm, greater than about 750 ppm, greater than about 1,000 ppm, greater than about 2,500 ppm, greater than about 5,000 ppm, greater than about 7,500 ppm, greater than about 10,000 ppm, and values therebetween. In certain embodiments, the furan or its derivatives may be present in an amount of about 4 ppm of the pet food.
[0171] In certain embodiments, when the flavor composition includes phosphate, the content of phosphate in the pet food can be about 1 mM to about 1 M of the pet food, or about 250 mM to about 1 M, or about 5 mM to about 500 mM, or about 10 mM to about 100 mM, or about 15 mM to about 50 mM, or about 20 mM to about 40 mM. In certain embodiments, the content of phosphate can be less than about 1 M, less than about 200 mM, less than about 100 mM, less than about 50 mM, less than about 20 mM, or less than about 10 mM of the pet food. In certain embodiments, the content of phosphate can be about 10 mM of the pet food.
[0172] In certain embodiments, when the flavor composition includes calcium chloride, the content of calcium chloride in the pet food can be about 1mM to about 1M of the pet food, or about 250mM to about 1M, or about 5mM to about 500mM, or about 10mM to about 100mM, or about 15mM to about 50mM, or about 20mM to about 40mM. In certain embodiments, the content of calcium chloride in the pet food can be about 1mM to about 20mM, about 5mM to about 20mM, or about 10mM to about 20mM, or about 10mM to about 15mM, or about 5mM to about 15mM, or about 5mM to about 10mM of the pet food. In certain embodiments, the content of phosphate can be less than about 1M, less than about 200mM, less than about 100mM, less than about 50mM, less than about 20mM, or less than about 10mM of the pet food. In certain embodiments, phosphate may be present in an amount of about 5 mM to about 15 mM of the pet food.
[0173] In certain embodiments, when the flavor composition comprises xanthan gum, the xanthan gum in the pet food can be present in an amount of about 1 g / L to about 10 g / L of the pet food, or about 1 g / L to about 9 g / L, or about 1 g / L to about 8 g / L, or about 1 g / L to about 7 g / L, or about 1 g / L to about 6 g / L, or about 1 g / L to about 5 g / L, or about 2 g / L to about 5 g / L, or about 2 g / L to about 6 g / L, or about 2 g / L to about 7 g / L, or about 2 g / L to about 8 g / L, or about 2 g / L to about 9 g / L, or about 3 g / L to about 4 g / L, or about 3 g / L to about 5 g / L, or about 3 g / L to about 6 g / L, or about 3 g / L to about 7 g / L of the pet food. In certain embodiments, the phosphate content can be less than about 10 g / L, less than about 9 g / L, less than about 8 g / L, less than about 7 g / L, less than about 6 g / L, or less than about 5 g / L of the pet food. In certain embodiments, the phosphate content can be from about 3 g / L to about 7 g / L of the pet food.
[0174] In certain embodiments, the present disclosure relates to a method for increasing the taste of a pet food, comprising a) providing at least one pet food or a precursor thereof, and b) combining the pet food (e.g., drinking water) with at least one flavor composition (e.g., comprising a first amino acid and a second amino acid) to form an enhanced pet food. In certain embodiments, the flavor composition comprises an allosteric modulator, such as a positive allosteric modulator.
[0175] 3.1. Exemplary Pet Foods
[0176] In some embodiments, the pet food is drinking water comprising a flavor composition comprising a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the first amino acid is present in an amount of about 100 mM of the pet food. In some embodiments, the second amino acid is present in an amount of about 100 mM of the pet food. In some embodiments, the pet food does not contain milk protein. In some embodiments, the pet food does not contain phosphates or derivatives thereof. In some embodiments, the pet food does not contain furans or derivatives thereof.
[0177] In some embodiments, the pet food is drinking water, which comprises a flavor composition consisting of a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the first amino acid is present in an amount of about 100 mM of the pet food. In some embodiments, the second amino acid is present in an amount of about 100 mM of the pet food.
[0178] In some embodiments, the pet food is drinking water, which comprises a flavor composition consisting of a first amino acid capable of activating an umami taste receptor, a second amino acid that cannot activate an umami taste receptor, a yeast extract, a mineral, and a phosphate. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the content of the first amino acid is about 100mM of the pet food. In some embodiments, the content of the second amino acid is about 100mM of the pet food. In some embodiments, the mineral is calcium chloride. In some embodiments, the phosphate is pyrophosphate.
[0179] In some embodiments, the pet food is drinking water, which comprises a flavor composition consisting of a first amino acid capable of activating an umami taste receptor, a second amino acid that cannot activate an umami taste receptor, a yeast extract, a mineral, a phosphate, and a thickener. In some embodiments, the first amino acid is histidine. In some embodiments, the second amino acid is proline. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1. In some embodiments, the content of the first amino acid is about 100mM of the pet food. In some embodiments, the content of the second amino acid is about 100mM of the pet food. In some embodiments, the mineral is calcium chloride. In some embodiments, the phosphate is pyrophosphate. In some embodiments, the thickener is xanthan gum.
[0180] In some embodiments, the pet food is drinking water comprising a flavor composition comprising a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3. In some embodiments, the first amino acid is present in an amount of about 20 mM to about 30 mM of the pet food. In some embodiments, the second amino acid is present in an amount of about 20 mM to about 30 mM of the pet food. In some embodiments, the pet food does not contain milk protein. In some embodiments, the pet food does not contain phosphates or derivatives thereof. In some embodiments, the pet food does not contain furans or derivatives thereof.
[0181] In some embodiments, the pet food is drinking water comprising a flavor composition comprising a first amino acid capable of activating an umami taste receptor and a second amino acid that cannot activate an umami taste receptor. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3. In some embodiments, the first amino acid is present in an amount of about 20 mM to about 30 mM of the pet food. In some embodiments, the second amino acid is present in an amount of about 20 mM to about 30 mM of the pet food.
[0182] In some embodiments, the pet food is drinking water comprising a flavor composition comprising a first amino acid capable of activating an umami taste receptor, a second amino acid that cannot activate an umami taste receptor, and a yeast extract. In some embodiments, the first amino acid is tyrosine. In some embodiments, the second amino acid is lysine. In some embodiments, the molar ratio of the first amino acid to the second amino acid is about 1:1.3. In some embodiments, the first amino acid is present in an amount of about 20 mM to about 30 mM of the pet food. In some embodiments, the second amino acid is present in an amount of about 20 mM to about 30 mM of the pet food.
[0183] In some embodiments, the pet food is drinking water comprising a flavor composition comprising milk protein and nucleotides. In some embodiments, the milk protein is casein hydrolysate. In some embodiments, the content of casein hydrolysate is about 3%. In some embodiments, the nucleotide is GMP. In some embodiments, the content of GMP is about 10mM of pet food. In some embodiments, the flavor composition also comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the content of furanone is about 4ppm of pet food. In some embodiments, the flavor composition also comprises phosphate. In some embodiments, the phosphate is pyrophosphate. In some embodiments, the content of phosphate is about 10mM of pet food.
[0184] In some embodiments, the pet food is drinking water comprising a flavor composition comprising milk protein and a nucleotide mixture. In some embodiments, the milk protein is a casein hydrolysate. In some embodiments, the content of the casein hydrolysate is about 3%. In some embodiments, the nucleotide mixture comprises GMP and IMP or consists of GMP and IMP. In some embodiments, the content of the nucleotide mixture is about 10mM of the pet food. In some embodiments, the flavor composition further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the content of furanone is about 4ppm of the pet food. In some embodiments, the flavor composition further comprises phosphate. In some embodiments, the phosphate is pyrophosphate. In some embodiments, the content of phosphate is about 10mM of the pet food.
[0185] In some embodiments, the pet food is drinking water comprising a flavor composition comprising milk protein and nucleotides. In some embodiments, the milk protein is casein hydrolysate. In some embodiments, the content of casein hydrolysate is about 3%. In some embodiments, the nucleotide is IMP. In some embodiments, the content of IMP is about 10mM of the pet food. In some embodiments, the flavor composition further comprises furan or a derivative thereof. In some embodiments, furan or a derivative thereof is furanone. In some embodiments, the content of furanone is about 4ppm of the pet food. In some embodiments, the flavor composition further comprises phosphate. In some embodiments, the phosphate is pyrophosphate. In some embodiments, the content of phosphate is about 10mM of the pet food.
[0186] 4. Formulation and delivery system
[0187] In certain embodiments, the flavor compositions or pet food disclosed herein may be included in a package. As used herein, the term "package" refers to one or more containers and is considered a unit for manufacture, distribution, sale or use. In certain non-limiting embodiments, the package includes a bag, box, case, bottle, packaging of any type or design or material, an outer packaging, a shrink wrap, a fixed part (e.g., stapling, bonding, etc.) or a combination thereof. In certain embodiments, the package may include drinking water containing the flavor compositions disclosed herein, which is considered a unit for manufacture, distribution, sale or use.
[0188] In certain embodiments, the present disclosure provides an effervescent composition comprising a flavor composition disclosed herein. The effervescent composition is based on the reaction of an acid and a carbonate to form carbon dioxide, and is known to autoly dissolve after being added to water. In certain embodiments, the effervescent composition includes an effervescent agent. In certain embodiments, the effervescent agent includes an alkali of an acid and a carbonate. For example, but not limited to, the effervescent agent may include phosphoric acid, citric acid, malic acid, tartaric acid, adipic acid, fumaric acid, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, or a combination thereof.
[0189] In some embodiments, the effervescent composition can be in the form of tablet or powder. Tablet form can be particularly useful because it can be conveniently packaged in a tube, foil or blister pack, convenient for user storage and carrying. In some embodiments, the effervescent composition can include additional components, such as a binder (e.g., glucose or lactose, or sorbitol) or a lubricant (e.g., polyethylene glycol, adipic acid or sodium benzoate).
[0190] In certain embodiments, the flavor composition of the present application can be incorporated into a delivery system for pet food. The delivery system can be liquid or solid, aqueous or non-aqueous. The delivery system is generally suitable for meeting the needs of the flavor composition and / or the pet food into which the flavor composition is to be incorporated.
[0191] In certain embodiments, the flavor composition can be used in liquid form, dry form and / or solid form. When used in dry form, a suitable drying method can be used, such as spray drying. Alternatively, the flavor composition can be encapsulated or absorbed on a water-soluble material, including but not limited to cellulose, starch, sugar, maltodextrin, gum arabic, etc. The actual technology for preparing such dry forms is well known in the art and can be applied to the subject matter of the present disclosure.
[0192] In certain embodiments, the flavor composition can be used in a variety of different physical forms known in the art to provide an initial burst of taste, flavor and / or texture; and / or a prolonged sensation of taste, flavor and / or texture. Such physical forms include, but are not limited to, free forms, such as spray-dried forms, powder forms and beaded forms and encapsulated forms and mixtures thereof.
[0193] In some embodiments, the flavor composition can be encapsulated wholly or in part. Encapsulation materials and / or technology can be selected to determine the modification type of flavor system. In some embodiments, encapsulation materials and / or technology are selected to improve the stability of flavor composition. In some embodiments, encapsulation materials and / or technology are selected to modify the release characteristics of flavor composition. Suitable encapsulation materials can include, but are not limited to, hydrophilic colloids (for example alginate, pectin, agar, guar gum, cellulose, etc.), proteins, polyvinyl acetate, polyethylene, cross-linked polyvinyl pyrrolidone, polymethyl methacrylate, polylactic acid, polyhydroxyalkanoate, ethyl cellulose, polyethylene acetate phthalate, polyethylene glycol ester, methacrylic acid-methyl methacrylate copolymer, ethylene-vinyl acetate (EVA) copolymer, etc., and combinations thereof. Suitable encapsulation techniques can include but are not limited to spraying, spray drying, spray cooling, absorption, adsorption, inclusion complexation (for example, forming flavor / cyclodextrin complex), cohesion, fluidized bed coating or other processes that can be used for encapsulating components with encapsulation materials. In certain embodiments, the encapsulated delivery system of the flavor composition can contain a hydrophobic matrix of fat or wax surrounding a sweetener or flavoring core. The fat can be selected from any number of conventional materials, such as fatty acids, glycerides or polyglycerol esters, sorbitol esters and mixtures thereof. Examples of fatty acids include, but are not limited to, hydrogenated and partially hydrogenated vegetable oils, such as palm oil, palm kernel oil, peanut oil, rapeseed oil, rice bran oil, soybean oil, cottonseed oil, sunflower seed oil, safflower oil and combinations thereof. Examples of glycerides include, but are not limited to, monoglycerides, diglycerides and triglycerides.
[0194] The wax may be selected from the group consisting of natural wax, synthetic wax and mixtures thereof. Non-limiting examples include paraffin, petrolatum, carbowax, microcrystalline wax, beeswax, carnauba wax, candelilla wax, lanolin, bayberry wax, sugar cane wax, spermaceti wax, rice bran wax and mixtures thereof.
[0195] The fat and wax can be used alone or in combination in an amount of about 10% to about 70%, or about 30% to about 60% by weight of the encapsulation system. When used in combination, the ratio of fat to wax can be about 70:10 to 85:15, respectively.
[0196] Typical encapsulated flavor compositions are disclosed in US Pat. Nos. 4,597,970 and 4,722,845, the disclosures of which are incorporated herein by reference in their entireties.
[0197] In certain embodiments, the flavor composition is contained in a liquid delivery system.In certain non-limiting embodiments, the liquid delivery system includes a system having a dispersion of the flavor composition disclosed herein, such as in a carbohydrate syrup and / or emulsion.
[0198] Additionally or alternatively, a solid delivery system can be used.Solid delivery systems can be manufactured by spray drying, spraying, spray cooling, fluidized bed drying, absorption, adsorption, cohesion, complexation or any other standard technology.In some embodiments, a delivery system compatible with edible compositions or playing a role in edible compositions can be selected.In some embodiments, the delivery system comprises oily materials, such as fat or oil.In some embodiments, the delivery system comprises confectionery fats and oils, such as cocoa butter, cocoa butter substitute, cocoa butter substitute or cocoa butter equivalent.When using in dry form, suitable drying methods can be used, such as spray drying.Alternatively, the flavor composition can be adsorbed or absorbed on the substrate, such as water-soluble materials that can be encapsulated, such as cellulose, starch, sugar, maltodextrin, gum arabic etc.The actual technology for preparing this type of dry form is well known in the art.
[0199] Treatment
[0200] The present disclosure provides a method for preventing, treating, and / or delaying the progression of chronic kidney disease (CKD) in an animal in need thereof. In addition, the present disclosure provides a method for preventing, treating, and / or delaying dehydration associated with chronic kidney disease (CKD) in an animal in need thereof. In certain embodiments, the method comprises administering a flavor composition or pet food disclosed herein. Chronic kidney disease (CKD) is a common clinical condition in cats of all ages, but is primarily diagnosed in cats over 10 years old, with a prevalence of 30%-40% in elderly cats (Sparkes et al., Journal of feline medicine and surgery 18(3), pp. 219-239, 2016). This condition is characterized by a gradual decline in renal function, leading to increased retention of phosphorus (P) and protein catabolites (McCarron, Journal of the American Society of Nephrology 16: S93-S94, 2005). During early CKD, this condition is compensated by increased glomerular pressure and filtration rate (Ames et al., J Vet Intern Med; 33:363-382, 2019), while calcium (Ca) and phosphorus balance is maintained by stimulation of the regulatory hormones fibroblast growth factor 23 (FGF-23) and parathyroid hormone (PTH) (Clarke, Endocrinology 152:4016-4018, 2011; Alexander et al., Br J Nutr; 121:1-21, 2019). However, in the long term, the above compensatory mechanisms become maladaptive, leading to progressive renal damage. Dietary management of cats with CKD aims to improve the progression of the disease and improve quality of life by correcting biochemical and mineral imbalances. The main characteristics of renal diets are reduced protein and phosphorus content while increasing caloric density and having a neutral effect on acid-base balance. Renal diets contain a higher calcium to phosphorus ratio (>1.5:1) compared to maintenance diets (<1.5:1). Studies in cats with early CKD (IRIS stages 1 and 2) provide clinical evidence for optimal levels of protein, phosphorus, calcium, and calcium to phosphorus ratio when managing cats long-term in the early stages of the disease based on kidney health parameters, calcium and phosphorus status, and mineral deposition in the urinary tract over a 43-month feeding period (Schauf et al., Journal of Veterinary Internal Medicine 35.6 (2021): 2797-2811).The results of these studies suggest that feeding a moderately protein-restricted and phosphorus-restricted diet on a mixed wet-dry regimen (each providing approximately 50% of maintenance energy requirements) can provide long-term greater stability of serum creatinine, urea, and FGF23 while controlling calcium and phosphorus balance in cats with hypercalcemia.
[0201] The International Renal Interest Society (IRIS) recommends feeding a veterinary therapeutic renal diet to cats with stages 2, 3, and 4 CKD, which refers to cats with high blood urea nitrogen and creatinine levels (azotemia) with or without proteinuria and hypertension. This recommendation is supported by many clinical trials in cats that have demonstrated the effectiveness of a renal diet in reducing the frequency of uremic crises (Harte et al., The Journal of Nutrition 124:2660S-2662S, 1994; Ross et al., Journal of the American Veterinary Medical Association 229:949-957, 2006) and improving median survival (Elliott et al., The Journal of Small Animal Practice 41:235-242, 2000; Ross et al., Journal of the American Veterinary Medical Association 229:949-957, 2006). As CKD progresses (usually in IRIS stages 3 and 4), the cat's ability to concentrate urine also begins to decline, and the cat will eventually begin to drink more water (polydipsia). In this setting, cats are more susceptible to dehydration, which can ultimately lead to worsening renal function, so feeding a moist diet with easy access to plenty of water is beneficial. Therefore, hydration therapy (including subcutaneous fluid administration) is often used in cats with advanced CKD. However, there is currently little information on the beneficial effects of increasing water intake in cats in the early stages of CKD (IRIS stages 1 and 2), a gap that this project aims to fill. Human studies have shown that increased water intake has beneficial effects on renal function in patients with various forms of CKD and those at risk for developing CKD, meaning that increased water intake appears to have a preventive effect in addition to helping alleviate disease symptoms after they develop (Clark et al., American journal of nephrology 43(4), pp. 281-292, 2016).
[0202] The present disclosure also provides a method for preventing, treating and / or delaying the progression of urinary tract diseases in animals in need thereof. In certain embodiments, the method comprises administering a flavor composition or pet food disclosed herein. As used herein, the term "urinary tract disease" refers to a range of mild to severe diseases occurring in the urinary tract (e.g., lower urinary tract), including structural and functional abnormalities of the bladder and urethra. The most common clinical signs of urinary tract disease include, for example, but are not limited to, difficult or painful urination, increased frequency of urination, crying out in pain during urination, blood in the urine, inappropriate urination (e.g., outside the litter box), or frequent licking of the genital area (Dorsch et al., Journal of Feline Medicine and Surgery 21, no. 11 (November 2019): 1023–38; Hostutler et al., Veterinary Clinics: Small Animal Practice 35, no. 1 (2005): 147–170).
[0203] In cats, urinary tract disease occurs primarily in middle-aged, overweight cats that are inactive, use indoor litter boxes, have little exposure to the outdoor environment, and / or drink less water. In addition, stressful environmental factors such as living in a multi-cat household and changes in daily life can also increase the risk of urinary tract disease in cats. Typically, the diagnosis of urinary tract disease is based on clinical symptoms (e.g., physical examination and urinalysis) and laboratory methods (e.g., blood tests, X-rays, abdominal ultrasound, and / or urine culture). The pathogenesis of urinary tract disease includes a variety of causes such as infection, inflammation, diet, and behavioral problems. For example, but not limited to, the causes of urinary tract disease include cystitis (including idiopathic cystitis), urinary tract stones, and urethral obstruction.
[0204] In certain embodiments, urinary tract disease is feline idiopathic cystitis (FIC). FIC is a urinary tract disease, and all diagnoses cannot confirm whether cats suffer from other diseases. Cats with FIC may frequently try to urinate due to bladder discomfort, and often find blood in the urine. Whether or not treated, the urinary tract disease symptoms of cats with FIC usually disappear within a few weeks, so most veterinarians treat the disease to prevent symptom recurrence. In certain embodiments, urinary tract disease is urinary tract stones. It is reported that uroliths (stones or stones in the urinary tract) are present in the urinary system of almost all animals, including dogs, cats, pigs, cattle, rabbits, horses, sheep, goats, deer, whales, birds and many other species. The most common types of urinary tract stones (uroliths) in cats are calcium oxalate (CaOx, CaC2O4) and struvite (magnesium ammonium phosphate, MAP, MgNH4PO4) stones, followed by urate. Uroliths account for one fifth of all veterinary visits due to urinary tract health in cats and are usually reported to occur in the bladder, although an increase in cases of kidneys and ureters has been reported in cats with renal failure. The incidence of these uroliths is related to the saturation of the relevant minerals in the urine. In certain embodiments, the urinary tract disease is urethral obstruction. Urinary obstruction is the most dangerous problem for cats with urinary tract disease. Urinary tract stones are only one of the causes of urethral obstruction. Another common cause is a urethral plug. A urethral plug is composed of a soft, compressible substance containing varying amounts of minerals, cells, and mucus-like proteins.
[0205] In certain embodiments, the animal is a feline or a canine. In certain embodiments, the animal is a feline. In certain embodiments, the animal is at risk for chronic kidney disease. In certain embodiments, it is not known if the animal is at risk for chronic kidney disease. In certain embodiments, the animal has chronic kidney disease. In certain embodiments, it is not known if the animal has chronic kidney disease. In certain embodiments, the animal is being treated for chronic kidney disease. In certain embodiments, the animal is at risk for urinary tract disease. In certain embodiments, it is not known if the animal is at risk for urinary tract disease. In certain embodiments, the animal has urinary tract disease. In certain embodiments, it is not known if the animal has urinary tract disease. In certain embodiments, the animal is being treated for urinary tract disease. In certain embodiments, the treatment is a diet.
[0206] In certain embodiments, the present disclosure provides a method for preventing, treating, or delaying the progression of chronic kidney disease (CKD) in animals. In certain embodiments, the present disclosure provides a method for preventing, treating, or delaying the progression of urinary tract disease in animals. In certain embodiments, the method comprises administering a flavor composition or pet food disclosed herein (see Sections 2 and 3).
[0207] In certain embodiments, the method further comprises administering a treatment regimen. In certain embodiments, the treatment regimen is selected from the group consisting of diet therapy, hemodialysis, renal replacement therapy, discontinuation of compounds that damage the kidney, renal transplantation, delaying or avoiding surgery that damages the kidney, changing diuretic administration, and combinations thereof. In certain embodiments, the treatment regimen is selected from the group consisting of administering a composition comprising an effective amount of magnesium or a salt thereof, reducing phosphate intake, reducing protein intake, administering polyunsaturated fatty acids, administering phosphate binder therapy, administering potassium, reducing dietary sodium intake, administering alkaline supplements, and combinations thereof. In certain embodiments, the treatment regimen includes Jonathan D. Forster, Update on Mineral and Bone Disorders in Chronic Kidney Disease. Vet Clin North Am Small Anim Pract. 2016 Nov; 46 (6): 1131-49) described in any treatment method, the contents of which are incorporated herein by reference as a whole.
[0208] In certain embodiments, the treatment regimen is a dietary therapy. In certain embodiments, the dietary therapy comprises a diet selected from the group consisting of a high magnesium diet, a low phosphorus diet, a low protein diet, a low sodium diet, a high potassium diet, a polyunsaturated fatty acid (PUFA) diet, and combinations thereof. In certain embodiments, the dietary therapy is Elliott et al., Dietary therapy for feline chronic kidney disease, Encyclopedia of feline clinical nutrition, 2nd ed., 2015. nd Any of the dietary therapies described in FDA's FDA Approval of Treatment for Infectious Diseases (edition, 2015), the contents of which are hereby incorporated by reference in their entirety.
[0209] In certain embodiments, the present disclosure provides a method for preventing, treating, or delaying the progression of chronic kidney disease (CKD) and / or urinary tract disease by increasing the water content of an animal that receives or has received a urinary tract dietary food containing sodium chloride or potassium chloride. In certain embodiments, the method comprises administering a flavor composition or pet food disclosed herein (see Sections 2 and 3).
[0210] In certain embodiments, the content of the flavor composition or pet food is from about 10 mg / kcal to about 1000 mg / kcal. For example, but not limited to, the content of the flavor composition or pet food can be from about 10 mg / kcal to about 100 mg / kcal, from about 20 mg / kcal to about 100 mg / kcal, from about 10 mg / kcal to about 200 mg / kcal, from about 20 mg / kcal to about 200 mg / kcal, from about 50 mg / kcal to about 100 mg / kcal, from about 50 mg / kcal to about 200 mg / kcal, from about 50 mg / kcal to about 300 mg / kcal, from about 100 mg / kcal to about 200 mg / kcal, from about 100 mg / kcal to about 300 mg / kcal, from about 100 mg / kcal to about 400 mg / kcal, from about 100 mg / kcal to about 500 mg / kcal, from about 2 In some embodiments, the flavor composition or pet food has a content of about 200 mg / kcal to about 500 mg / kcal, for example, about 200 mg / kcal to about 600 mg / kcal, about 200 mg / kcal to about 700 mg / kcal, about 200 mg / kcal to about 800 mg / kcal, about 300 mg / kcal to about 600 mg / kcal, about 300 mg / kcal to about 700 mg / kcal, about 300 mg / kcal to about 800 mg / kcal, about 400 mg / kcal to about 600 mg / kcal, about 400 mg / kcal to about 700 mg / kcal, about 400 mg / kcal to about 800 mg / kcal or about 500 mg / kcal to about 800 mg / kcal. In some embodiments, the flavor composition or pet food has a content of about 200 mg / kcal to about 500 mg / kcal, for example, about 300 mg / kcal. In certain embodiments, the flavor composition or pet food contains about 50 mg / kcal to about 200 mg / kcal, for example, about 100 mg / kcal.
[0211] In some embodiments, the flavor composition or pet food can be fed to the animal in a constant manner, for example, the animal can eat a continuous and effective supply of the flavor composition or pet food. In some embodiments, the flavor composition or pet food can be fed to the animal three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, or once a month. In some embodiments, the flavor composition or pet food can be fed to the animal once or more every day. For example, but not limited to, the flavor composition or pet food can be applied once, twice, three times, four times, five times or more times a day.
[0212] Example
[0213] The presently disclosed subject matter will be better understood by reference to the following examples, which are provided by way of illustration and not limitation of the invention.
[0214] Example 1 - Determination of the ability of flavor compositions to increase water intake in healthy adult cats.
[0215] This example investigated whether adding a flavor composition of the present disclosure to drinking water would increase voluntary free water intake compared to unflavored / blank water in a monadic test in healthy adult cats.
[0216] Materials and methods
[0217] Cat drinking water test method: The monadic test method used in this example is described in Table 1 below.
[0218] Table 1: Summary of methods.
[0219]
[0220]
[0221] Experimental Design. Briefly, six groups of adult cats were divided into two shifts of 12 cats each and worked alternately in a staggered manner (two days of testing and two days of rest) as described in Table 2 below.
[0222] Table 2: Experimental design used. Product rotation by group.
[0223]
[0224] Data Collection and Analysis. The following measurements were collected at specific time intervals for each trial: body weight and body condition score (measured at the beginning of each trial and weekly thereafter); cabin temperature (temperature of the cabin area was measured once daily); solution temperature before offering; food offered and rejected (morning feeding and afternoon feeding, per cat per day); weight of solution offered and rejected (per cat per day); aqueous solution pH; evaporation (evaporation of the solution was measured twice daily); and additional instructions. Dunnett's test was performed at the 5% level using 6 pairwise comparisons between each flavor composition solution and deionized water.
[0225] Flavor Compositions Tested. Detailed descriptions of the flavor composition solutions tested are shown below in Table 3. The flavor compositions tested included three flavor compositions based on casein hydrolysate (B, D, and F) and three flavor compositions based on amino acid mixtures (C, E, and G).
[0226] Table 3: Flavour compositions tested.
[0227]
[0228] result
[0229] Figure 1 Graphical results for flavor compositions versus water are shown. The average intake of all six flavor compositions studied was significantly higher than the average intake of no flavor / blank water. The intake of flavor compositions based on casein hydrolysate (B=153 g, D=148 g, and F=168 g) was higher than the intake of flavor compositions based on amino acid mixtures (C=102 g, E=105 g, and G=129 g).
[0230] Since sodium (Na+) has a potential impact on the intake of each flavor composition, the sodium content of the different flavor compositions was calculated. The sodium in the flavor composition studies came from casein hydrolysate, GMP (disodium form), or pyrophosphate (trisodium pyrophosphate). The casein hydrolysate used in this study had a sodium content of 2.5%. The Na+ content of the other two ingredients was 1.5%. + The content can be calculated by stoichiometry. Thus, the sodium content of the flavor compositions based on casein hydrolysate (B, D and F) is 0.98 g / L, 0.98 g / L and 1.67 g / L, respectively, while the sodium content of the flavor compositions based on amino acids (C, E and G) is 0.23 g / L, 0.23 g / L and 0.92 g / L, respectively.
[0231] All flavor solutions had significantly higher intakes than deionized water, meaning that, in a single case, adding a flavor to water encouraged cats to drink more water compared to unflavored / blank water. The extent to which total daily intake per cat increased depended on the flavor type, with flavors containing casein hydrolyzate having higher intakes than amino acid-based flavors.
[0232] A supplementary analysis was performed on the effect of the flavor composition type (casein hydrolyzate-based or amino acid-based). The presentation of the mean intake according to the flavor composition type was not performed using the Dunnett test, but using the Tukey test. Significant differences were found between the different types, p<0.001. Figure 2 Means with 95% confidence intervals are shown. All differences were significant.
[0233] in conclusion
[0234] Water intake was increased in cats in a single test situation. When mean intake was compared using Dunnett's test, intake of all six flavor compositions was significantly higher than water. These results suggest that adding flavor compositions to water can increase water intake in healthy adult cats.
[0235] Example 2 - Determination of the ability of flavor compositions to increase water intake in cats with early-stage chronic kidney disease (CKD).
[0236] This example investigates whether adding the flavor composition of the present disclosure to drinking water will increase voluntary water intake in cats identified as asymptomatic and stable early CKD (IRIS stage 1 or 2; nephrotic cats). Currently, it is unclear whether water intake can be increased in cats with early CKD by adding the flavor composition of the present disclosure to their water, as their drinking behavior may differ for physiological and / or clinical reasons.
[0237] Materials and methods
[0238] Cat Water Drinking Test Method. The method involved two 22-hour exposures of 16 cats with stable early CKD to water and each flavored solution as described in Table 4.
[0239] Table 4: Summary of drinking water test method.
[0240]
[0241]
[0242] Cohort of Early CKD Cats - Health, Behavior, and Water Testing Background. A total of 16 cats (age range 6.5-13.3 years at trial entry, mean age 9.4 years) participated in the study. Cats were diagnosed with early CKD and were clinically stable at IRIS stage 1 (11 / 16 cats) and IRIS stage 2 (5 / 16 cats) based on serum creatinine, symmetric dimethylarginine (SDMA), systolic blood pressure, proteinuria, renal ultrasound, and urinary tract imaging. Among the IRIS stage 2 cats, three had kidney / ureteral stones and one had bladder stones. Four of the 16 cats had a previous clinical history of feline idiopathic cystitis. Cats in this cohort were habituated to the equipment used in the study in advance.
[0243] Experimental design
[0244] Initially, the cats were tested in a "pre-feeding" water phase (Phase 1; Table 5) to habituate them to the cat cup waterer. The purpose of the pre-feeding phase was only to collect behavioral data and habituate the cats to the waterer and accommodation, but these data were not used to measure baseline water intake. The second phase of the trial was a water baseline test, which was conducted without the addition of the flavor composition of the present disclosure. After this phase, the next three tests (Phase 3, 4 and 5) provided the three different flavor compositions tested (see Table 5) in a randomized manner, providing a total of 5 test blocks for each cat:
[0245] Phase 1: Water T0 (habituation, training and behavioral observations - data not used for analysis).
[0246] • Phase 2: Water TO (Baseline Water - the basis for comparison with the 3 flavor compositions tested).
[0247] • Phase 3: Flavor composition scheme (X, Y or Z, depending on the randomization group).
[0248] • Phase 4: Flavor composition scheme (X, Y or Z, depending on the randomization group).
[0249] • Phase 5: Flavor composition scheme (X, Y or Z, depending on the randomization group).
[0250] For each stage, due to the availability of the huts required for individual drinking water tests, 16 cats were tested in a staggered manner (Table 5). In each 48-hour test period, each cat was housed alone for a total of 44 hours. During the test phase, two hours of social time were provided every 24 hours, during which no drinking water was available. Each drinking water test consisted of repeated exposures, in which a single aqueous solution was provided to the cat. Each test phase was followed by a 9-day rest phase. On rest days, cats lived normally in larger social groups and had free access to water.
[0251] Table 5: Solution rotation by cat group.
[0252]
[0253] Diet and feeding regimen. Each cat in the cohort had a different food form (dry or wet) depending on medical and / or behavioral needs. The water content of the diet was 78.3% for the wet diet and 4.7% for the dry diet, and this water content was used in the calculation of total water intake. Most cats in the cohort were fed a mixed wet and dry feeding regimen, with each form providing approximately 50% of maintenance energy requirements. The exceptions were four cats with a past history of feline idiopathic cystitis, who received all meals with a level of moisture as recommended by their veterinarian. Additional water was also added to the meals of some of these cats. Two cats were fed three meals a day instead of two. However, this feeding regimen was only implemented on rest days, and on test days, dry food was provided to the cats in the hut.
[0254] The tested aqueous solutions. Table 6 below shows the specifications of the tested flavor composition solutions. More details about the flavor mixtures:
[0255] X: Consists of 100 mM cat umami active amino acid (L-histidine) and 100 mM cat non-umami active amino acid (L-proline).
[0256] Y: consists of 266 mM (or 2%) of cat umami-active amino acids (glycine) and 20 mM of cat non-umami-active amino acids (L-threonine).
[0257] Z: consists of 266 mM (or 2%) cat umami-active amino acid (glycine), 20 mM cat non-umami-active amino acid (L-threonine), and 4 ppm furanone.
[0258] The water used for the drinking water tests was mineral water (Highland Spring 1.5 L) to avoid taste variations. The flavor compositions tested were all prepared with the same water and were selected based on the specific needs of cats with IRIS stage 1 or 2 CKD. These restrictions included no added phosphorus or calcium that could disrupt the calcium-phosphorus ratio, consideration of amino acid type, and limiting the content of sodium and other salts.
[0259] Table 6: Solutions tested.
[0260] serial number Code Solution letter Compound Name 1 T0 Baseline A Highland Spring Mineral Water 2 X Flavor 1 B 100mM L-histidine + 100mM L-proline 3 Y Flavor 2 C 2% Glycine + 20mM L-Threonine 4 Z Flavor 3 D 2% glycine + 20mM L-threonine + 4ppm furanone
[0261] Data Collection and Analysis. The following measurements were collected for each cat at specific intervals throughout the study. Body weight and body condition scores were measured at the beginning of each phase and weekly thereafter. The amount of food provided and refused at the morning and afternoon feedings each day and at any additional meals. The amount of water and flavor composition solution provided and refused each test day. The pH of the flavor composition solution, evaporation, and additional notes (e.g., any observed behavioral traits or medications administered to individual cats during the experiment) were also recorded. All raw water and flavor solution intake data were corrected for evaporation and any reported spillage.
[0262] Two variables were used in the analysis: (1) free aqueous solution intake and (2) total water intake, calculated as the sum of free water intake and the water content of the diet consumed. Because body weight and body surface area affect water intake, the data set contains two calculated values: grams per kilogram body weight and grams per kilogram metabolic body weight (kg BW). 0.711 ). A linear mixed effects model was fitted using data collected from baseline water and water with added flavor composition. The variables group, flavor composition, and the interaction between the two were fixed effects, while individual animals were random effects. A likelihood ratio test was also performed to assess the significance of group and interaction to the model. If these were considered non-significant, only the flavor composition variable was used as a fixed effect. If the group was considered non-significant, no stage effect was found. Residuals were visually assessed to determine whether the normality assumption was met. If they were considered not normally distributed, a logarithmic transformation or appropriate non-parametric test was applied. If the variance was not considered uniform, the flavor composition was weighted. Estimated means were extracted and reported with 95% CI. A Dunnett test was then performed to compare flavor composition intake with baseline water. Estimated differences or fold changes were obtained and reported together with 95% CI and p-values. Statistically significant differences were determined by p-values ≤ 0.05. All analyses were performed using R version 3.6.3.
[0263] result
[0264] Four cats fed a 100% wet diet had very low water intake during the pre-feeding phase (Phase 1). After consultation with the attending veterinarian, these four cats were transitioned to a mixed wet-dry regimen in the following phase, so all cats were on a wet-dry regimen for the remainder of the study. In addition, free water and total water intake were examined after each phase as the study progressed, and it was found that some cats increased their water intake as the trial progressed, while others did the opposite. It is important to note that it may be difficult to separate the effects of the flavor composition from the behavioral effects of accommodation. Therefore, it was decided to conduct an additional water baseline phase (Phase 6) at the end of the study to be able to detect differences in water drinking behavior from the beginning to the end of the study (see Table 7 below).
[0265] Table 7: Final six-stage experimental design.
[0266]
[0267] Of the 16 cats that started the study, three dropped out of the study at various time points. Therefore, 12 cats completed two water baselines (Phase 1 - Water Baseline 1 and Phase 6 - Water Baseline 2) plus three flavor composition phases (Phase 3, 4, and 5). The statistical analysis of flavor composition intake included 13 cats because one cat had been exposed to the first water baseline and all flavor compositions but did not participate in the second water baseline.
[0268] Before the study (Phase 2-Baseline 1) and at the end of the study (Phase 6-Baseline 2; Table 8, Figure 3 ) showed a difference of 21.9 g in free water intake, but it did not reach significance (p value of 0.074). Therefore, no evidence of changes in responses during the study period was found. Based on the above results, Baseline 1 was therefore considered a valid benchmark for evaluating the effects of the flavor composition solutions on water intake and was used in all subsequent analyses.
[0269] When analyzing free water intake for water baseline 1 and flavor composition solutions, a preliminary statistical check (likelihood ratio test) was performed to determine if there was any group effect or test time effect for the cats. The results of this check were not significant (p value of 0.460). A second statistical test was performed to determine if there was any flavor composition group interaction effect, which was also not significant (p value of 0.497).
[0270] Table 8: Water intake for different flavour compositions, showing means and 95% confidence intervals (CI) and p-values for the difference in water intake relative to plain water intake at the start of the study (Baseline 1).
[0271]
[0272] 1 Total water intake includes water intake from meals.
[0273] Table 8 and Figure 4 Mean free water intake for the different flavor compositions is provided. When the difference from the water baseline at the start of the study for each flavor composition was analyzed using Dunnett's test, only one flavor composition, X, was observed to be significantly different (difference from water was 25 g, p value was 0.028), while no significant differences were observed for the other two flavor compositions (difference from water was 12.4 g, p value was 0.302 for Y and 16.6 g, p value was 0.051 for Z). The difference in Z indicated a trend. The percentage increase in free water intake achieved by each flavor composition compared to the baseline was 10.7% for Y, 15.2% for Z, and 22.3% for X.
[0274] For total water intake (free water intake + water intake from food), the interaction effects of group and flavor composition*group were examined and were not significant. The difference between flavor composition and water was significant for X (25 g difference compared to water, p-value 0.027), but not for the other two groups (12.4 g difference compared to water, p-value 0.303 for Y and 16.6 g difference compared to water, p-value 0.052 for Z), again indicating a trend in favor of Z. The percent increase in total water intake achieved by each flavor composition compared to baseline was 10.2% for Y, 14.4% for Z, and 21.2% for X. When the intake was expressed as grams of water intake per kilogram of body weight, the results showed that the difference between the flavor composition and water was 2.84 g / Kg body weight (p value 0.347) for Y, 3.42 g / Kg body weight (p value 0.054) for Z, and 5.24 g / Kg body weight (p value 0.044) for X. Again, X resulted in a significant increase in intake per kilogram of body weight.
[0275] Expressed as grams of intake per kilogram of metabolic body weight (g*Kg BW 0.711 ) also identified X as a flavor composition that significantly increased total water intake (p = 0.050; see Tables 8 and Figure 5 ). For Y, the difference between the flavor composition and water was 1.03 g / Kg metabolic body weight (p value was 0.372); for Z, the difference was 1.12 g / Kg metabolic body weight (p value was 0.304); for X, the difference was 1.75 g / Kg metabolic body weight (p value was 0.050).
[0276] discuss
[0277] Of the three flavor compositions tested, X, which consisted of a high concentration (100 mM) of a feline umami-active amino acid (L-histidine) and a high concentration (100 mM) of a feline non-umami-active amino acid (L-proline), significantly increased water intake in a cohort of cats with early-stage CKD according to all calculated parameters.
[0278] in conclusion
[0279] Of the 3 flavor compositions tested in this study, Flavor Composition X performed best, significantly increasing all measures of water intake in a cohort of 16 cats with early stable CKD (IRIS1-2) over a single 48-hour exposure. These results suggest that the addition of X to water can influence water intake in cats with early CKD.
[0280] Example 3 - Providing a functional beverage in addition to water to promote additional water intake and diuretic effects in cats fed a dry diet.
[0281] This example investigates the effect of providing water enhanced with certain flavor compositions disclosed herein in addition to plain water to cats fed a dry diet on total water intake and urine parameters.
[0282] To promote water intake and urine dilution and reduce relative supersaturation of calcium oxalate (RSS CaOx) and MAP in cats fed a dry diet, a common strategy (at least in urine diets) is to increase water intake by feeding a wet diet or increasing sodium chloride or potassium chloride in the dry diet. However, there is great interest in exploring alternative strategies to promote greater water intake and urine dilution.
[0283] Therefore, it is necessary to develop a flavor composition that can increase the spontaneous water volume in cats, promote urine dilution and reduce relative supersaturation (RSS).
[0284] In addition to the effects on water intake and urine parameters, this example also evaluates whether the effects of two diets that promote different levels of spontaneous water intake are similar. In particular, it was evaluated whether i) providing a palatable beverage in addition to a maintenance (conventional) dry diet can replace providing a dry diet for urinary tract disease to increase water intake and diuresis and reduce the risk of urinary crystals, and ii) whether providing a palatable beverage in addition to a dry diet for urinary tract disease has additional benefits compared to providing a dry diet for urinary tract disease alone. It is assumed that when such a palatable beverage is provided in any manner, whether it is fed a conventional diet or a diet for urinary tract disease, cats will drink more fluid per day, resulting in increased urine volume and reduced RSS values.
[0285] Materials and Methods
[0286] The protocol used two commercially available dry feline diets: a dry diet for urinary tract disease and a regular dry cat food diet. The two diets were fed sequentially to 14 healthy adult cats divided into 2 experimental groups (panels) in a standard digestibility / RSS study in an incomplete crossover design.
[0287] In addition to traditional digestibility and RSS measurements, the intake of water was recorded (weighed) with and without flavor composition F supplementation. The weight (grams) of the measured liquid was converted to volume (ml) using the density of the given liquid (measured for flavor composition F).
[0288] Solutions were prepared on the day of testing or the day before to ensure freshness. If prepared the day before, they were placed in a refrigerator at 4°C until feeding testing.
[0289] The preparation of flavor composition F was more difficult than expected due to slow dissolution of the ingredients during stirring. In addition, some sediment could be seen in the cats' bowls several hours after feeding, so the animal keepers needed to stir the solution regularly during the feeding trial to ensure proper dissolution.
[0290] Statistical analysis
[0291] Linear mixed models (mixed procedure of SAS) were used to assess the effects of diet type, use of supplemented beverages (e.g., flavor composition F) (e.g., supplemented (SUPP), not supplemented (NO SUPP)), and cat panel and their respective interactions as fixed effects on several parameters (e.g., food and fluid intake and urine parameters). Cats were included as random terms because each cat was its own control. Output variables were either sorted or not sorted according to the residual distribution of each model. Differences between 2 fixed effect levels were assessed by Scheffe's test (e.g., adjusted for multiple comparisons). To assess differences in flavor composition F intake for each diet, the model included only diet as a fixed effect and cat as a random term. Data are expressed as least squares means ± SE (unless otherwise stated). The significance level was set at 0.05.
[0292] Results - Discussion
[0293] After consultation, four cats (one from the urinary tract disease diet and three from the conventional diet) were excluded because they met the exclusion rules for RSS calculation (e.g., only one urine sample was collected during the collection period). Therefore, the final statistical model included urine-related parameters for 13 cats fed the urinary tract disease diet and urine-related parameters for 11 cats fed the conventional diet. For diet and fluid intake data, all cats (n=14) were included.
[0294] The results and corresponding statistical analysis are reported below in Tables 9 and 10, respectively. There were no panel effects for any of the parameters.
[0295] Table 9. LS means, SE or medians obtained for the cat test groups for each diet with or without F. The dry diet for urinary tract disease is labeled "UrinaryDiet".
[0296]
[0297] Table 10. P values obtained from the general linear model.
[0298]
[0299] It was observed that caloric intake by diet alone was generally different with diet (urine > regular) and significantly lower with flavor composition F ( Figure 6 ). In addition, differences in body weight (BW) between the different diets were found. Of note, the differences were not dependent on the supplementation of flavor composition F. However, the body weight changes for the total group ranged from -2.7% to +4.1% over the entire study period (8 weeks), while for a given RSS test (2 weeks), the body weight changes ranged from -6.1% to +4.7%. Therefore, the differences in body weight between the different diets are not considered to be biologically relevant ( Figure 7 ).
[0300] Next, it was observed that, for both diets, sodium intake (g / day) was significantly higher when flavor composition F was provided ( Figure 8 For a given diet, the intake of flavor composition F varied among cats, ranging from 4 ml / kg / d to 58.8 ml / kg / d ( Fig. 9 Total flavor composition F intake (ml / kg / d) did not differ by the diet tested (urine or regular) (p=0.32) ( Fig.10 ). Notably, spontaneous water intake (ml / kg / d) was significantly lower when Flavor Composition F was provided in addition to water. When total liquid intake (water + Flavor Composition F) was considered, total liquid intake was significantly higher for both diets when Flavor Composition F was provided ( Fig.11 ).
[0301] Urine parameters were also analyzed. Urine volume (mL / kg / d) increased significantly when flavor composition F was provided with the regular diet. This was not found despite the higher fluid intake with the urine diet ( Fig. 12A and Fig. 12B In addition, when the supplemental beverage flavor composition F was provided, urine specific gravity was significantly reduced ( Fig.13A and Fig. 13B ).
[0302] It was observed that the urine pH of the regular diet was significantly higher than that of the urine diet. When flavor composition F was provided, the urine pH of the regular diet was significantly increased ( Fig.14A and Fig. 14B ).
[0303] RSS analysis was also performed in this example. The RSS MAP of the regular diet was significantly higher than that of the urine diet and was not affected by the supplement ( Fig.15 In addition, RSS CaOx was significantly reduced in both diets when flavor composition F was provided ( Fig.16A For most cats, RSS CaOx decreases when supplementation is provided ( Fig. 16B ). Although no statistical analysis was performed, RSS CaOx was lower in all cats that consumed ≥20 mL / kg / day of Flavor Composition F, regardless of diet. For the regular diet, 4 of the 5 cats that consumed <20 mL / kg / day of Flavor Composition F had increased RSS CaOx, while 1 cat had a decreased RSS. Notably, there was a significant inverse linear correlation (R2=0.43) between the intake of Flavor Composition F and the RSS values of the cats ( Fig. 16C , Fig.16D , Fig.17 and Fig.18 ).
[0304] Conclusion - Viewpoint
[0305] Overall, this example shows that the use of flavor composition F significantly increased water intake in healthy cats. Specifically, a 50% increase in regular diet and a 28% increase in urine diet were observed. Importantly, the amount of flavor composition F consumed varied among cats, but was generally well accepted.
[0306] Drinking Flavor Composition F generally resulted in lower urine specific gravity, higher urine pH (+0.27 for regular diet, +0.17 for urine diet), same RSS struvite, lower RSS CaOx (-49% for regular diet, -33% for urine diet). Finally, it was observed that i) the addition of Flavor Composition F to the regular diet resulted in lower RSS CaOx, but higher RSS struvite, compared to feeding the urine diet alone; ii) the addition of Flavor Composition F to the urine diet improved urinary function (lower RSS CaOx and similar RSS struvite) compared to feeding the urine diet alone.
[0307] In summary, this example shows that providing flavor composition F achieves similar RSS CaOx as providing a urinary dry diet, but with higher RSS struvite. In addition, flavor composition F reduces RSS CaOx (and maintains RSS struvite) regardless of whether a dry diet is fed. Therefore, the flavor compositions and pet foods disclosed herein can present and treat urinary tract diseases.
[0308] ***
[0309] Although the subject matter of the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and variations can be made herein without departing from the spirit and scope of the present application defined by the appended claims. In addition, the scope of the present application is not intended to be limited to the specific implementation of the process, machine, manufacture, material composition, device, method and step described in the specification. As will be easily understood by those of ordinary skill in the art from the disclosure of the subject matter of the present disclosure, according to the subject matter of the present disclosure, it is possible to utilize the process, machine, manufacture, material composition, device, method or step with the function substantially the same as the corresponding embodiment described herein or the result substantially the same as that of the present disclosure that will be developed later. Therefore, the appended claims are intended to include such process, machine, manufacture, material composition, device, method or step within its scope.
[0310] For any patents, patent applications, publications, product descriptions, and protocols cited in this application, the disclosures of all of these are incorporated herein by reference in their entirety for all purposes.
Claims
1. A method for preventing and / or treating chronic kidney disease in an animal in need thereof, the method comprising administering a pet food comprising a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
2. A method for preventing and / or treating a urinary tract disease in an animal in need thereof, the method comprising administering a pet food comprising a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
3. A method for increasing water intake of an animal, the method comprising administering a pet food containing milk protein and nucleotides or derivatives thereof.
4. A method of increasing hydration in an animal, the method comprising administering a pet food comprising milk protein and nucleotides or derivatives thereof.
5. A method for preventing and / or treating chronic kidney disease in an animal in need thereof, the method comprising milk protein and nucleotides or derivatives thereof.
6. A method for preventing and / or treating urinary tract diseases in an animal in need thereof, the method comprising milk protein and nucleotides or derivatives thereof.
7. The method according to claim 1 or 2, wherein: The first amino acid is alanine, histidine, glycine, serine, tyrosine or a mixture thereof.
8. The method according to claim 1 or 2, wherein: The second amino acid is proline, hydroxyproline, valine, threonine, lysine or a mixture thereof.
9. The method according to claim 1 or 2, wherein a) the first amino acid is alanine, histidine, glycine, serine, tyrosine or a mixture thereof, and the second amino acid is proline, hydroxyproline, valine, threonine, lysine or a mixture thereof; b) the first amino acid is histidine, and the second amino acid is proline, hydroxyproline, valine, threonine, lysine or a mixture thereof; or c) the first amino acid is alanine, histidine, glycine, serine, tyrosine or a mixture thereof, and the second amino acid is proline.
10. The method according to claim 9, wherein: The first amino acid is histidine and the second amino acid is proline.
11. The method according to claim 9, wherein: The molar ratio of the first amino acid to the second amino acid is about 1:
1.
12. The method according to claim 9, wherein: The molar ratio of the first amino acid to the second amino acid is about 1:1.
3.
13. The method according to claim 9, wherein: The amount of each of the first amino acid and the second amino acid is about 1 mM to about 1M.
14. The method according to claim 9, wherein: The amount of each of the first amino acid and the second amino acid is about 100 mM.
15. The method according to claim 9, wherein: The amount of each of the first amino acid and the second amino acid is about 20 mM to about 50 mM.
16. The method according to claim 1 or 2, wherein a) the pet food does not contain phosphates or their derivatives; and / or b) The pet food does not contain furan or its derivatives.
17. The method according to claim 1 or 2, wherein: The pet food also includes yeast extract.
18. The method according to any one of claims 3 to 6, wherein: The milk protein is casein or a derivative thereof.
19. The method according to any one of claims 3 to 6, wherein: The amount of milk protein is from about 1 wt % to about 10 wt %.
20. The method according to claim 19, wherein: The amount of milk protein was about 3% by weight.
21. The method according to any one of claims 3 to 6, wherein: The nucleotide or its derivative is AMP, UMP, GMP, IMP, CMP, or a mixture thereof.
22. The method according to claim 21, wherein: The nucleotide mixture comprises GMP and IMP.
23. The method according to claim 21, wherein: The nucleotide or its derivative is GMP.
24. The method according to claim 21, wherein: The nucleotide or derivative thereof is an IMP.
25. The method according to claim 21, wherein: The nucleotides or their derivatives are obtained from yeast extract.
26. The method according to claim 25, wherein: The yeast extract is a Kluyveromyces extract, a Torula yeast extract or a Saccharomyces cerevisiae extract.
27. The method according to any one of claims 3 to 6, wherein: The amount of the nucleotide or its derivative is about 1 mM to about 100 mM.
28. The method according to claim 27, wherein: The amount of the nucleotide or its derivative is about 5 mM.
29. The method according to any one of claims 3 to 6, wherein: The pet food further comprises furan or a derivative thereof.
30. The method of claim 29, wherein: The furan or its derivative is furanone.
31. The method of claim 29, wherein: The amount of furan or its derivatives is about 1 ppm to about 100 ppm.
32. The method according to claim 31, wherein: The amount of furan or its derivatives was about 4 ppm.
33. The method according to any one of claims 1 to 6, wherein: The pet food further comprises phosphate or a derivative thereof.
34. The method of claim 33, wherein: The phosphate is pyrophosphate.
35. The method of claim 33, wherein: The amount of phosphate is from about 1 mM to about 1M.
36. The method of claim 35, wherein: The amount of phosphate was about 10 mM.
37. The method of claim 17, wherein: The pet food further comprises phosphate or a derivative thereof.
38. The method according to any one of claims 3 to 6, wherein: The pet food further comprises furan or its derivatives and phosphate or its derivatives.
39. The method according to any one of claims 1 to 6, wherein: The pet food may further comprise one or more vitamins, minerals, antioxidants, thickeners, or combinations thereof.
40. The method according to any one of claims 1 to 6, wherein: The pet food is drinking water.
41. The method according to claim 40, wherein: The drinking water is packaged drinking water.
42. The method according to any one of claims 1 to 6, wherein: The animal is a feline.
43. A pet food for use in preventing and / or treating chronic kidney disease in an animal in need thereof, wherein: The pet food comprises a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
44. A pet food for use in preventing and / or treating urinary tract diseases in an animal in need thereof, wherein: The pet food comprises a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor.
45. A pet food for increasing the amount of water consumed by an animal, wherein: The pet food comprises milk protein and nucleotides or derivatives thereof.
46. A pet food for increasing animal hydration, wherein: The pet food comprises milk protein and nucleotides or derivatives thereof.
47. A pet food for use in preventing and / or treating chronic kidney disease in an animal in need thereof, wherein: The pet food comprises milk protein and nucleotides or derivatives thereof.
48. A pet food for use in preventing and / or treating urinary tract diseases in an animal in need thereof, wherein: The pet food comprises milk protein and nucleotides or derivatives thereof.
49. The pet food for use according to claim 43 or 44, wherein The first amino acid is alanine, histidine, glycine, serine, tyrosine or a mixture thereof.
50. Pet food for use according to any one of claims 43, 44 and 49, wherein The second amino acid is proline, hydroxyproline, valine, threonine, lysine or a mixture thereof.
51. A pet food for use according to any one of claims 43, 44, 49 and 50, wherein The first amino acid is histidine and the second amino acid is proline.
52. Pet food for use according to any one of claims 43 to 44 and 49 to 51, wherein The molar ratio of the first amino acid to the second amino acid is about 1:
1.
53. Pet food for use according to any one of claims 43 to 44 and 49 to 51, wherein The molar ratio of the first amino acid to the second amino acid is about 1:1.
3.
54. Pet food for use according to any one of claims 43 to 44 and 49 to 53, wherein The amount of each of the first amino acid and the second amino acid is about 1 mM to about 1M.
55. Pet food for use according to any one of claims 43 to 44 and 49 to 54, wherein The amount of each of the first amino acid and the second amino acid is about 100 mM.
56. Pet food for use according to any one of claims 43 to 44 and 49 to 54, wherein The amount of each of the first amino acid and the second amino acid is about 20 mM to about 50 mM.
57. Pet food for use according to any one of claims 43 to 44 and 49 to 56, wherein a) the pet food does not contain phosphates or their derivatives; and / or b) The pet food does not contain furan or its derivatives.
58. Pet food for use according to any one of claims 43 to 44 and 49 to 56, wherein The pet food also includes yeast extract.
59. Pet food for use according to any one of claims 45 to 48, wherein The milk protein is casein or a derivative thereof.
60. Pet food for use according to any one of claims 45 to 48 and 59, wherein The amount of milk protein is from about 1 wt % to about 10 wt %.
61. Pet food for use according to any one of claims 45 to 48, 59 and 60, wherein The amount of milk protein was about 3% by weight.
62. Pet food for use according to any one of claims 45 to 48 and 59 to 61, wherein The nucleotide or its derivative is AMP, UMP, GMP, IMP, CMP or a mixture thereof.
63. Pet food for use according to any one of claims 45 to 48 and 59 to 62, wherein The nucleotides or their derivatives are obtained from yeast extract.
64. The pet food for use according to claim 63, wherein: The yeast extract is a Kluyveromyces extract, a Torula yeast extract or a Saccharomyces cerevisiae extract.
65. Pet food for use according to any one of claims 45 to 48 and 59 to 64, wherein The amount of the nucleotide or its derivative is about 1 mM to about 100 mM.
66. Pet food for use according to any one of claims 45 to 48 and 59 to 65, wherein The amount of the nucleotide or its derivative is about 5 mM.
67. Pet food for use according to any one of claims 45 to 48 and 59 to 66, wherein The pet food further comprises furan or a derivative thereof.
68. The pet food for use according to claim 67, wherein The furan or its derivative is furanone.
69. The pet food for use according to claim 67 or 68, wherein The amount of furan or its derivatives is about 1 ppm to about 100 ppm.
70. Pet food for use according to any one of claims 67 to 69, wherein The amount of furan or its derivatives was about 4 ppm.
71. Pet food for use according to any one of claims 45 to 48 and 59 to 70, wherein The pet food further comprises phosphate or a derivative thereof.
72. The pet food for use according to claim 71, wherein The phosphate is pyrophosphate.
73. The pet food for use according to claim 71 or 72, wherein The amount of phosphate is from about 1 mM to about 1M.
74. The pet food for use according to claim 73, wherein The amount of phosphate was about 10 mM.
75. Pet food for use according to any one of claims 43 to 74, wherein The pet food may further comprise one or more vitamins, minerals, antioxidants, thickeners, or combinations thereof.
76. Pet food for use according to any one of claims 43 to 75, wherein The pet food is drinking water.
77. The pet food for use according to claim 76, wherein The drinking water is packaged drinking water.
78. Pet food for use according to any one of claims 44 to 79, wherein The animal is a feline.
79. A flavor composition, comprising: a) a first amino acid capable of activating an umami taste receptor and a second amino acid incapable of activating an umami taste receptor; b) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, and a yeast extract; c) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, yeast extract, minerals and phosphate; d) a first amino acid capable of activating an umami taste receptor, a second amino acid incapable of activating an umami taste receptor, yeast extract, minerals, phosphates and a thickener; e) milk proteins and nucleotides or their derivatives; f) milk proteins, nucleotides or their derivatives and furans or their derivatives; or g) milk proteins, nucleotides or their derivatives, furans or their derivatives, and phosphates or their derivatives.
80. The flavor composition of claim 79, wherein The first amino acid is histidine, and the second amino acid is proline.
81. The flavor composition of claim 79 or 80, wherein The molar ratio of the first amino acid to the second amino acid is about 1:1 or about 1:1.
3.
82. The flavor composition of claim 79, wherein The milk protein is casein or a derivative thereof.
83. The flavor composition of claim 79 or 82, wherein The nucleotide or its derivative is AMP, UMP, GMP, IMP, CMP or a mixture thereof.
84. The flavor composition of claim 83, wherein The nucleotide or its derivative is GMP.
85. The flavor composition of claim 83, wherein The nucleotide or derivative thereof is an IMP.
86. The flavor composition of claim 83, wherein The nucleotide mixture comprises GMP and IMP.
87. The flavor composition of claim 79, wherein The furan or its derivative is furanone.
88. The flavor composition of claim 79, wherein The phosphate is pyrophosphate.
